(Convenience Translation into English from the Original Previously Issued in Portuguese)

Dimed S.A. Distribuidora de Medicamentos

Individual and Consolidated
Interim Financial Information for the
Quarter Ended June 30, 2026 and
Report on Review of Interim
Financial information

Deloitte Touche Tohmatsu Auditores Independentes Ltda.

Contents

Company Information / Capital Breakdown

Number of shares (unit)	Current Quarter 06/30/2026
Paid-in capital	
Common shares	150,377,481
Preferred shares	-
Total	150,377,481
Treasury shares	
Common shares	1,001,855
Preferred shares	-
Total	1,001,855

Individual Financial Statements / Balance sheet - Assets
(In thousands of reais)

Account Code	Account Description	Current Quarter 06/30/2026	Prior Year 12/31/2025
1	Total assets	3,687,369	3,834,448
1.01	Current assets	2,109,328	2,253,270
1.01.01	Cash and Cash Equivalents	59,265	42,541
1.01.02	Short-term investments	199,902	376,761
1.01.02.01	Financial Assets Measured at Fair Value Through Profit or Loss	199,902	376,761
1.01.02.01.03	Short-term investments	199,902	376,761
1.01.03	Accounts receivable	637,782	664,971
1.01.03.01	Trade accounts receivable	547,966	567,462
1.01.03.02	Other trade receivables	89,816	97,509
1.01.04	Inventories	1,176,821	1,142,616
1.01.06	Taxes recoverable	30,083	26,381
1.01.06.01	Current taxes recoverable	30,083	26,381
1.01.06.01.01	Income Tax and Social Contribution Recoverable	4,884	3,560
1.01.06.01.02	Other taxes recoverable	25,199	22,821
1.01.08	Other Current Assets	5,475	-
1.01.08.03	Other	5,475	-
1.01.08.03.02	Other Assets Short Term	5,475	-
1.02	Noncurrent Assets	1,578,041	1,581,178
1.02.01	Long-term Assets	63,742	71,084
1.02.01.07	Deferred taxes	43,525	50,254
1.02.01.07.01	Deferred income and social contribution taxes	43,525	50,254
1.02.01.08	Prepaid expenses	708	1,300
1.02.01.10	Other noncurrent assets	19,509	19,530
1.02.01.10.03	Other taxes recoverable	14,562	14,465
1.02.01.10.04	Judicial deposits	3,307	4,205
1.02.01.10.05	Other assets	1,640	860
1.02.02	Investments	87,288	81,095
1.02.02.01	Equity interest	87,288	81,095
1.02.02.01.02	Interest in Subsidiaries	78,222	72,842
1.02.02.01.04	Other investments	9,066	8,253
1.02.03	Property, plant and equipment (PPE)	1,320,161	1,321,838
1.02.03.01	Property, plant and equipment (PPE) in operation	576,324	580,266
1.02.03.02	Right-of-use assets - Lease	706,730	718,797
1.02.03.03	PP&E in progress	37,107	22,775
1.02.04	Intangible assets	106,850	107,161
1.02.04.01	Intangible assets	106,850	107,161
1.02.04.01.02	Intangible assets	106,850	107,161

Individual Financial Statements / Balance sheet - Liabilities and Equity
(In thousands of reais)

Account Code	Account Description	Current Quarter 06/30/2026	Prior Year 12/31/2025
2	Total liabilities	3,687,369	3,834,448
2.01	Current liabilities	1,247,185	1,347,377
2.01.01	Social and labor obligations	106,692	84,088
2.01.01.01	Social obligations	20,139	21,066
2.01.01.02	Labor obligations	86,553	63,022
2.01.02	Trade accounts payable	655,844	734,761
2.01.02.01	Trade accounts payable - domestic	655,844	734,761
2.01.02.01.01	Trade accounts payable - domestic	653,887	734,761
2.01.02.01.02	Trade accounts payable - forfaiting	1,957	-
2.01.03	Tax obligations	79,162	55,562
2.01.03.01	Federal tax obligations	6,587	17,902
2.01.03.01.01	Income tax and social contribution payable	602	5,864
2.01.03.01.02	Other federal tax obligations	5,985	12,038
2.01.03.02	State tax obligations	70,346	35,554
2.01.03.03	Local tax obligations	2,229	2,106
2.01.04	Loans and financing	280,155	322,849
2.01.04.01	Loans and financing	16,210	110,912
2.01.04.01.01	In domestic currency	16,210	110,912
2.01.04.02	Debentures	124,040	75,048
2.01.04.03	Financing through lease	139,905	136,889
2.01.05	Other obligations	113,926	141,592
2.01.05.01	Liabilities with related parties	-	27,000
2.01.05.01.03	Payables to controllers	-	27,000
2.01.05.02	Other	113,926	114,592
2.01.05.02.01	Dividends and interest on equity payable	48,270	23,948
2.01.05.02.04	Profit sharing payable	-	18,190
2.01.05.02.05	Other liabilities	65,656	67,100
2.01.05.02.06	Derivative financial instruments	-	5,354
2.01.06	Provisions	11,406	8,525
2.01.06.01	Provisions for tax, social security, labor and civil contingencies	11,406	8,525
2.01.06.01.05	Other provisions	11,406	8,525
2.02	Noncurrent liabilities	1,123,165	1,205,220
2.02.01	Loans and financing	1,098,745	1,155,780
2.02.01.01	Loans and financing	139,254	138,378
2.02.01.01.01	In domestic currency	139,254	138,378
2.02.01.02	Debentures	310,000	360,000
2.02.01.03	Financing through lease	649,491	657,402
2.02.02	Other obligations	16,918	42,805
2.02.02.02	Other	16,918	42,805
2.02.02.02.03	Interest on equity	7,810	34,070
2.02.02.02.04	Other obligations	9,108	8,735
2.02.04	Provisions	7,502	6,635
2.02.04.01	Provisions for tax, social security, labor and civil contingencies	7,502	6,635
2.02.04.01.02	Provisions for social security and labor contingencies	7,502	6,635
2.03	Equity	1,317,019	1,281,851
2.03.01	Paid-in Capital	1,279,584	1,212,695
2.03.01.01	Capital	1,294,032	1,227,143
2.03.01.02	Share issue costs	-14,448	-14,448
2.03.02	Capital reserves	-19,220	-21,786
2.03.02.05	Treasury shares	-10,292	-21,359
2.03.02.07	Goodwill reserve	-13,024	-8,233
2.03.02.08	Long-term incentive reserve	4,096	7,806
2.03.04	Profits reserve	24,053	90,942
2.03.04.01	Legal reserve	24,053	24,053
2.03.04.10	Capital increase reserve	-	66,889
2.03.05	Retained earnings/accumulated losses	32,602	-

Individual Financial Statements / Statement of Profit or Loss

(In thousands of reais)

Account Code	Account Description	Current Quarter 04/01/2026 to 06/30/2026	Current Year Accumulated 01/01/2026 to 06/30/2026	Same prior-year Quarter 04/01/2025 to 06/30/2025	Prior Year Accumulated 01/01/2025 to 06/30/2025
3.01	Revenue from sales of goods and/or services	1,506,478	2,944,351	1,310,452	2,566,196
3.01.01	Gross sales of products and services	1,631,015	3,186,614	1,408,961	2,760,815
3.01.02	Sales taxes	-107,653	-208,991	-83,083	-165,041
3.01.03	Returns and unconditional discounts	-16,884	-33,272	-15,426	-29,578
3.02	Cost of sales and/or services	-1,016,368	-1,999,142	-879,258	-1,737,207
3.03	Gross income	490,110	945,209	431,194	828,989
3.04	Operating income/expenses	-423,361	-810,109	-375,370	-718,906
3.04.01	Selling expenses	-374,853	-723,135	-327,484	-646,737
3.04.02	General and administrative expenses	-55,785	-102,477	-47,127	-88,878
3.04.04	Other operating income	6,376	10,124	-167	15,387
3.04.06	Equity method income	901	5,379	-592	1,322
3.05	Income before finance income and taxes	66,749	135,100	55,824	110,083
3.06	Finance income (costs)	-31,941	-63,616	-28,349	-53,695
3.06.01	Finance income	8,354	23,666	9,793	27,430
3.06.02	Finance costs	-40,295	-87,282	-38,142	-81,125
3.07	Income before income taxes	34,808	71,484	27,475	56,388
3.08	Income and social contribution taxes	-4,437	-7,882	-2,385	-5,832
3.08.01	Current	-602	-1,153	609	-3,302
3.08.02	Deferred	-3,835	-6,729	-2,994	-2,530
3.09	Net income from continuing operations	30,371	63,602	25,090	50,556
3.11	Profit/Loss for the period	30,371	63,602	25,090	50,556
3.99	Earnings per share (reais / share)				
3.99.01	Basic earnings per share				
3.99.01.01	Registered common shares	0.21	0.43	0.17	0.34
3.99.02	Diluted earnings per share				
3.99.02.01	Registered common shares	0.2	0.42	0.17	0.34

Individual Financial Statements / Statement of Comprehensive Income

(In thousands of reais)

Account Code	Account Description	Current Quarter 04/01/2026 to 06/30/2026	Current Year Accumulated 01/01/2026 to 06/30/2026	Same prior-year Quarter 04/01/2025 to 06/30/2025	Prior Year Accumulated 01/01/2025 to 06/30/2025
4.01	Net profit for the period	30,371	63,602	25,090	50,556
4.02	Other comprehensive income	-	-	-427	-307
4.03	Comprehensive income for the period	30,371	63,602	24,663	50,249

Individual Financial Statements / Statement of Cash Flows (Indirect Method) (In thousands of reais)

Account Code	Account Description	Current YTD 01/01/2026 to 06/30/2026	Prior YTD 01/01/2025 to 06/30/2025
6.01	Net cash flows from operating activities	169,548	224,811
6.01.01	Cash generated from operations	252,876	211,597
6.01.01.01	Net income for the period	63,602	50,556
6.01.01.02	Depreciation and amortization	123,667	114,095
6.01.01.03	Provision for contingent liabilities	867	468
6.01.01.04	Equity pickup	-5,379	-1,322
6.01.01.05	Cost of permanent assets written off/sold	1,655	504
6.01.01.06	Allowance for doubtful accounts	1,747	- 207
6.01.01.07	Provision for inventory losses	- 23	47
6.01.01.08	Stock option plan or stock subscription	3,012	2,534
6.01.01.09	Deferred income and social contribution taxes	6,729	2,530
6.01.01.10	Current income and social contribution taxes	1,153	3,302
6.01.01.11	Appropriation of interest on loans and financing	31,670	11,454
6.01.01.12	Appropriation of lease interest	39,940	34,162
6.01.01.13	Appropriation of cost on loans	1,010	-
6.01.01.14	Interest income from financial investments	-17,055	-6,526
6.01.01.15	Exchange variation of financial investments	281	-
6.01.02	Changes in assets and liabilities	- 83,328	13,214
6.01.02.01	Credits receivable from customers	17,749	-12,848
6.01.02.02	Inventories	- 34,182	63,191
6.01.02.03	Trade accounts payable	- 80,874	-28,873
6.01.02.04	Trade accounts payable - forfaiting	1,957	-
6.01.02.05	Taxes, contributions and social obligations	47,167	4,158
6.01.02.06	Judicial deposits	898	-34
6.01.02.07	IRPJ and CSLL paid	-963	-5,615
6.01.02.08	Taxes recoverable	-4,952	393
6.01.02.09	Other asset groups	1,216	25,551
6.01.02.10	Other liability groups	-31,344	-32,709
6.02	Net cash flows from investing activities	132,913	-119,599
6.02.01	Acquisition of property, plant and equipment (PPE)	-45,845	-48,776
6.02.02	Acquisition of intangible assets	-14,875	-18,145
6.02.03	Financial Investments	-123,507	-133,837
6.02.04	Redemption of financial investments	317,140	81,159
6.03	Net cash flows from financing activities	-285,737	-136,904
6.03.01	Payment of dividends and interest on equity	-28,799	-26,233
6.03.02	Acquisition of own shares	-2,137	-1,780
6.03.03	Loans and financing funding	-	90,000
6.03.04	Commercial lease payment	-66,797	-65,529
6.03.05	Lease interest payment	-39,940	-34,162
6.03.06	Amortization of financing principal	-90,000	-120,000
6.03.07	Amortization of financing interest	-37,345	-31,107
6.03.08	Shares granted matching shares plan	6,472	1,907
6.03.09	Loans with related parties	-27,000	50,000
6.03.10	Interest paid on loans with related parties	-191	-
6.05	Increase (decrease) in cash and cash equivalents	16,724	-31,692
6.05.01	Cash and cash equivalents at beginning of period	42,541	78,903
6.05.02	Cash and cash equivalents at the end of the period	59,265	47,211

Individual Financial Statements / Statement of Changes in Equity / SCE - 01/01/2026 to 06/30/2026
(In thousands of reais)

Account Code	Account Description	Paid-in capital	Capital reserves, options granted and treasury shares	Income Reserves	Retained earnings (accumulated losses)	Other comprehensive income	Equity
5.01	Opening balances	1,212,695	-21,786	90,942	-	-	1,281,851
5.02	Prior-year adjustments	-	-	-	-	-	-
5.03	Adjusted opening balances	1,212,695	-21,786	90,942	-	-	1,281,851
5.04	Capital transactions with shareholders	66,889	2,566	-66,889	-31,000	-	-28,434
5.04.01	Capital increase	66,889	-	-66,889	-	-	-
5.04.03	Recognized granted options	-	4,194	-	-	-	4,194
5.04.04	Treasury shares acquired	-	-2,137	-	-	-	-2,137
5.04.07	Interest on equity	-	-	-	-31,000	-	-31,000
5.04.08	Fair value of the Matching Shares Plan	-	3,012	-	-	-	3,012
5.04.09	Disposal/transfer of shares	-	-2,503	-	-	-	-2,503
5.05	Total comprehensive income	-	-	-	63,602	-	63,602
5.05.01	Net profit for the period	-	-	-	63,602	-	63,602
5.07	Closing balance	1,279,584	-19,220	24,053	32,602	-	1,317,019

Individual Financial Statements / Statement of Changes in Equity / SCE - 01/01/2025 to 06/30/2025
(In thousands of reais)

.Account Code	Account Description	Paid-in capital	Capital reserves, options granted and treasury shares	Income reserves	Retained earnings (accumulated losses)	Other comprehensive income	Equity
5.01	Opening balances	981,773	-21,537	273,683	-	795	1,234,714
5.02	Prior-year adjustments	-	-	-	-	-	-
5.03	Adjusted opening balances	981,773	-21,537	273,683	-	795	1,234,714
5.04	Capital transactions with shareholders	50,238	1,372	-75,176	-26,500	-	-50,066
5.04.01	Capital increase	50,238	-	-50,238	-	-	-
5.04.03	Recognized granted options	-	1,907	-	-	-	1,907
5.04.04	Treasury shares acquired	-	-1,780	-	-	-	-1,780
5.04.06	Dividends	-	-	-24,938	-	-	-24,938
5.04.07	Interest on equity	-	-	-	-26,500	-	-26,500
5.04.08	Disposal/transfer of shares	-	-1,289	-	-	-	-1,289
5.04.09	Fair value of the Matching Shares Plan	-	2,534	-	-	-	2,534
5.05	Total comprehensive income	-	-	-	50,556	-1,102	49,454
5.05.01	Net profit for the period	-	-	-	50,556	-	50,556
5.05.02	Other comprehensive income	-	-	-	-	-1,102	-1,102
5.07	Closing balance	1,032,011	-20,165	198,507	24,056	-307	1,234,102

Individual Financial Statements / Statement of Value Added
(In thousands of reais)

Account Code	Account Description	Current YTD 01/01/2026 to 06/30/2026	Prior YTD 01/01/2025 to 06/30/2025
7.01	Revenue	3,373,466	2,970,100
7.01.01	Sales of goods, products and services	3,153,343	2,731,237
7.01.02	Other revenue	221,869	238,656
7.01.04	Reversal of/allowance for expected credit losses	-1,746	207
7.02	Inputs acquired from third parties	-2,368,770	-2,092,294
7.02.01	Cost of products, goods and services	-2,125,502	-1,885,359
7.02.02	Material, energy, services from third parties and other	-258,521	-218,670
7.02.03	Loss/Recovery of assets	15,253	11,735
7.03	Gross value added	1,004,696	877,806
7.04	Retentions	-123,667	-114,095
7.04.01	Depreciation, amortization and depletion	-123,667	-114,095
7.05	Net value added generated	881,029	763,711
7.06	Value added received in transfer	29,897	29,448
7.06.01	Equity pickup	5,379	1,322
7.06.02	Finance income	24,518	28,126
7.07	Total value added distributable	910,926	793,159
7.08	Distribution of value added	910,926	793,159
7.08.01	Personnel	350,437	318,283
7.08.01.01	Direct Remuneration	290,953	257,055
7.08.01.02	Benefits	34,036	38,487
7.08.01.03	Severance Indemnity Fund (FGTS)	25,448	22,741
7.08.02	Taxes, charges and contributions	387,050	322,929
7.08.02.01	Federal	109,063	99,843
7.08.02.02	State	272,076	217,262
7.08.02.03	Local	5,911	5,824
7.08.03	Remuneration of third-party capital	109,837	101,391
7.08.03.01	Interest	87,639	82,112
7.08.03.02	Rent	22,198	19,279
7.08.04	Equity remuneration	63,602	50,556
7.08.04.01	Interest on Equity (IOE)	31,000	26,500
7.08.04.03	Retained Profits/Loss for the period	32,602	24,056

Consolidated Financial Statements / Balance sheet - Assets
(In thousands of reais)

Account Code	Account Description	Current Year 06/30/2026	Prior Year 12/31/2025
1	Total assets	3,709,889	3,830,510
1.01	Current assets	2,185,277	2,297,587
1.01.01	Cash and Cash Equivalents	59,995	43,745
1.01.02	Short-term investments	235,203	386,751
1.01.02.01	Financial Assets Measured at Fair Value Through Profit or Loss	235,203	386,751
1.01.02.01.03	Short-term investments	235,203	386,751
1.01.03	Accounts receivable	646,261	672,045
1.01.03.01	Trade accounts receivable	555,937	574,182
1.01.03.02	Other trade receivables	90,324	97,863
1.01.04	Inventories	1,204,480	1,166,554
1.01.06	Taxes recoverable	33,449	28,078
1.01.06.01	Current taxes recoverable	33,449	28,078
1.01.06.01.01	Income Tax and Social Contribution Recoverable	6,434	5,124
1.01.06.01.02	Other taxes recoverable	27,015	22,954
1.01.08	Other Current Assets	5,889	414
1.01.08.01	Non-Current Assets for Sale	414	414
1.01.08.01.01	Properties available for sale	414	414
1.01.08.03	Other	5,475	-
1.01.08.03.02	Other Assets Short Term	5,475	-
1.02	Noncurrent Assets	1,524,612	1,532,923
1.02.01	Long-term Assets	73,735	80,779
1.02.01.07	Deferred taxes	53,518	59,949
1.02.01.07.01	Deferred income and social contribution taxes	53,518	59,949
1.02.01.08	Prepaid expenses	708	1,300
1.02.01.10	Other noncurrent assets	19,509	19,530
1.02.01.10.03	Other taxes recoverable	14,562	14,465
1.02.01.10.04	Judicial deposits	3,307	4,205
1.02.01.10.05	Other assets	1,640	860
1.02.02	Investments	9,065	8,253
1.02.02.01	Equity interest	9,065	8,253
1.02.02.01.05	Other investments	9,065	8,253
1.02.03	Property, plant and equipment (PPE)	1,333,501	1,335,365
1.02.03.01	Property, plant and equipment (PPE) in operation	589,664	593,793
1.02.03.02	Right-of-use assets - Lease	706,730	718,797
1.02.03.03	PP&E in progress	37,107	22,775
1.02.04	Intangible assets	108,311	108,526
1.02.04.01	Intangible assets	108,311	108,526
1.02.04.01.02	Intangible assets	108,311	108,526

Consolidated Financial Statements / Balance sheet - Liabilities and Equity
(In thousands of reais)

Account Code	Account Description	Current Year 06/30/2026	Prior Year 12/31/2025
2	Total liabilities	3,709,889	3,830,510
2.01	Current liabilities	1,249,876	1,320,670
2.01.01	Social and labor obligations	108,565	85,488
2.01.01.01	Social obligations	20,525	21,474
2.01.01.02	Labor obligations	88,040	64,014
2.01.02	Trade accounts payable	644,285	725,307
2.01.02.01	Trade accounts payable - domestic	644,285	725,307
2.01.02.01.01	Trade accounts payable - domestic	642,328	725,307
2.01.02.01.02	Trade accounts payable - forfaiting	1,957	-
2.01.03	Tax obligations	83,598	59,637
2.01.03.01	Federal tax obligations	7,906	19,722
2.01.03.01.01	Income tax and social contribution payable	1,350	6,790
2.01.03.01.02	Other federal tax obligations	6,556	12,932
2.01.03.02	State tax obligations	73,459	37,803
2.01.03.03	Local tax obligations	2,233	2,112
2.01.04	Loans and financing	286,187	328,704
2.01.04.01	Loans and financing	22,242	116,767
2.01.04.01.01	In domestic currency	22,242	116,767
2.01.04.02	Debentures	124,040	75,048
2.01.04.03	Financing through lease	139,905	136,889
2.01.05	Other obligations	115,761	112,947
2.01.05.02	Other	115,761	112,947
2.01.05.02.01	Dividends and interest on equity payable	48,270	23,948
2.01.05.02.04	Profit sharing payable	-	18,401
2.01.05.02.05	Other liabilities	67,491	65,244
2.01.05.02.06	Derivative financial instruments	-	5,354
2.01.06	Provisions	11,480	8,587
2.01.06.01	Provisions for tax, social security, labor and civil contingencies	11,480	8,587
2.01.06.01.05	Other provisions	11,480	8,587
2.02	Noncurrent liabilities	1,142,994	1,227,989
2.02.01	Loans and financing	1,117,563	1,177,561
2.02.01.01	Loans and financing	158,072	160,159
2.02.01.01.01	In domestic currency	158,072	160,159
2.02.01.02	Debentures	310,000	360,000
2.02.01.03	Financing through lease	649,491	657,402
2.02.02	Other obligations	16,918	42,805
2.02.02.02	Other	16,918	42,805
2.02.02.02.03	Interest on equity	7,810	34,070
2.02.02.02.04	Other obligations	9,108	8,735
2.02.04	Provisions	8,513	7,623
2.02.04.01	Provisions for tax, social security, labor and civil contingencies	8,513	7,623
2.02.04.01.01	Tax Provisions	918	884
2.02.04.01.02	Provisions for social security and labor contingencies	7,595	6,739
2.03	Equity	1,317,019	1,281,851
2.03.01	Paid-in Capital	1,279,584	1,212,695
2.03.01.01	Capital	1,294,032	1,227,143
2.03.01.02	Share issue costs	-14,448	-14,448
2.03.02	Capital reserves	-19,220	-21,786
2.03.02.05	Treasury shares	-10,292	-21,359
2.03.02.07	Goodwill reserve	-13,024	-8,233
2.03.02.08	Long-term incentive reserve	4,096	7,806
2.03.04	Profits reserve	24,053	90,942
2.03.04.01	Legal reserve	24,053	24,053
2.03.04.10	Capital increase reserve	-	66,889
2.03.05	Retained earnings/accumulated losses	32,602	-

Consolidated Financial Statements / Statement of Profit or Loss
(In thousands of reais)

Account Code	Account Description	Current Quarter 04/01/2026 to 06/30/2026	Current Year Accumulated 01/01/2026 to 06/30/2026	Same Prior-Year Quarter 04/01/2025 to 06/30/2026	Prior Year Accumulated 01/01/2025 to 06/30/2025
3.01	Revenue from sales of goods and/or services	1,509,150	2,958,811	1,313,746	2,572,434
3.01.01	Gross sales of products and services	1,635,294	3,206,107	1,413,727	2,770,423
3.01.02	Sales taxes	-108,721	-213,096	-84,146	-166,774
3.01.03	Returns and unconditional discounts	-17,423	-34,200	-15,835	-31,215
3.02	Cost of sales and/or services	-1,015,225	-2,002,198	-880,241	-1,737,834
3.03	Gross income	493,925	956,613	433,505	834,600
3.04	Operating income/expenses	-427,446	-821,967	-378,410	-726,176
3.04.01	Selling expenses	-376,995	-727,318	-329,734	-650,317
3.04.02	General and administrative expenses	-57,048	-104,981	-48,438	-91,304
3.04.04	Other operating income	6,597	10,332	-238	15,445
3.05	Income before finance income and taxes	66,479	134,646	55,095	108,424
3.06	Finance income (costs)	-31,120	-62,111	-27,489	-51,546
3.06.01	Finance income	9,662	26,093	10,668	30,158
3.06.02	Finance costs	-40,782	-88,204	-38,157	-81,704
3.07	Income before income taxes	35,359	72,535	27,606	56,878
3.08	Income and social contribution taxes	-4,988	-8,933	-2,516	-6,322
3.08.01	Current	-1,349	-2,501	-49	-5,042
3.08.02	Deferred	-3,639	-6,432	-2,467	-1,280
3.09	Net income from continuing operations	30,371	63,602	25,090	50,556
3.11	Profit/Loss for the period	30,371	63,602	25,090	50,556
3.11.01	Assigned to Partners of the Parent Company	30,371	63,602	25,090	50,556
3.99	Earnings per share (reais / share)				
3.99.01	Basic earnings per share				
3.99.01.01	Registered common shares	0.21	0.43	0.17	0.34
3.99.02	Diluted earnings per share				
3.99.02.01	Registered common shares	0.2	0.42	0.17	0.34

Consolidated Financial Statements/ Statement of Comprehensive Income
(In thousands of reais)

Account Code	Account Description	Current Quarter 04/01/2026 to 06/30/2026	Current Year Accumulated 01/01/2026 to 06/30/2026	Same Prior-Year Quarter 04/01/2025 to 06/30/2025	Same Prior-Year Accumulated 01/01/2025 to 06/30/2025
4.01	Net profit for the period	30,371	63,602	25,090	50,556
4.02	Other comprehensive income	-	-	-427	-307
4.03	Comprehensive income for the period	30,371	63,602	24,663	50,249
4.03.01	Assigned to Partners of the Parent Company	30,371	63,602	24,663	50,249

Consolidated Financial Statements / Statement of Cash Flows (Indirect Method)
(In thousands of reais)

Account Code	Account Description	Current YTD 01/01/2026 to 06/30/2026	Prior YTD 01/01/2025 to 06/30/2025
6.01	Net cash flows from operating activities	169,199	221,288
6.01.01	Cash generated from operations	258,515	211,637
6.01.01.01	Net income for the period	63,602	50,556
6.01.01.02	Depreciation and amortization	124,453	114,878
6.01.01.03	Provision for contingent liabilities	890	557
6.01.01.04	Cost of permanent assets written off/sold	1,697	556
6.01.01.05	Allowance for doubtful accounts	1,747	-207
6.01.01.06	Provision for inventory losses	22	217
6.01.01.09	Stock option plan or stock subscription	3,012	2,534
6.01.01.10	Deferred income and social contribution taxes	6,432	1,280
6.01.01.11	Current income and social contribution taxes	2,501	5,042
6.01.01.12	Appropriation of interest on loans and financing	32,351	11,657
6.01.01.13	Appropriation of lease interest	39,940	34,162
6.01.01.14	Appropriation of cost on loans	1,010	-
6.01.01.15	Interest income from financial investments	-19,499	-9,595
6.01.01.16	Exchange variation of financial investments	281	-
6.01.01.17	Receipt for sale of fixed assets	3,000	-
6.01.01.18	Net Compensation of Retired Fixed Assets	-2,924	-
6.01.02	Changes in assets and liabilities	-89,316	9,651
6.01.02.01	Credits receivable from customers	16,498	-12,901
6.01.02.02	Inventories	-37,948	62,962
6.01.02.03	Trade accounts payable	-82,979	-30,603
6.01.02.04	Trade accounts payable - forfaiting	1,957	-
6.01.02.06	Taxes, contributions and social obligations	49,139	6,677
6.01.02.07	Judicial deposits	898	-34
6.01.02.08	IRPJ and CSLL paid	-2,101	-7,911
6.01.02.09	Taxes recoverable	-7,970	-1,518
6.01.02.10	Other asset groups	1,064	26,415
6.01.02.11	Other liability groups	-27,874	-33,436
6.02	Net cash flows from investing activities	109,233	-72,011
6.02.01	Acquisition of property, plant and equipment (PPE)	-46,406	-50,161
6.02.02	Acquisition of intangible assets	-15,127	-18,473
6.02.03	Financial Investments	-162,080	-145,201
6.02.04	Redemption of financial investments	332,846	141,824
6.03	Net cash flows from financing activities	-262,182	-181,605
6.03.01	Payment of dividends and interest on equity	-28,799	-26,233
6.03.02	Acquisition of own shares	-2,137	-1,780
6.03.03	Loans and financing funding	-	95,342
6.03.04	Commercial lease payment	-66,797	-65,529
6.03.05	Lease interest payment	-39,940	-34,162
6.03.06	Amortization of financing principal	-92,740	-120,000
6.03.08	Amortization of financing interest	-38,241	-31,150
6.03.10	Shares granted matching shares plan	6,472	1,907
6.05	Increase (decrease) in cash and cash equivalents	16,250	-32,328
6.05.01	Cash and cash equivalents at beginning period	43,745	79,995
6.05.02	Cash and cash equivalents at the end of period	59,995	47,667

Consolidated Financial Statements / Statement of Changes in Equity - SCE - 01/01/2026 to 06/30/2026
(In thousands of reais)

Account Code	Account Description	Paid-in capital	Capital reserves, options granted and treasury shares	Income reserves	Retained earnings (accumulated losses)	Other comprehensive income	Equity	Noncontrolling interests	Consolidated equity
5.01	Opening balances	1,212,695	-21,786	90,942	-	-	1,281,851	-	1,281,851
5.02	Prior-year adjustments	-	-	-	-	-	-	-	-
5.03	Adjusted opening balances	1,212,695	-21,786	90,942	-	-	1,281,851	-	1,281,851
5.04	Capital transactions with shareholders	66,889	2,566	-66,889	-31,000	-	-28,434	-	-28,434
5.04.01	Capital increase	66,889	-	-66,889	-	-	-	-	-
5.04.03	Recognized granted options	-	4,194	-	-	-	4,194	-	4,194
5.04.04	Treasury shares acquired	-	-2,137	-	-	-	-2,137	-	-2,137
5.04.07	Interest on equity	-	-	-	-31,000	-	-31,000	-	-31,000
5.04.08	Fair value of the Matching Shares Plan	-	3,012	-	-	-	3,012	-	3,012
5.04.09	Disposal/ transfer of shares	-	-2,503	-	-	-	-2,503	-	-2,503
5.05	Total comprehensive income	-	-	-	63,602	-	63,602	-	63,602
5.05.01	Net profit for the period	-	-	-	63,602	-	63,602	-	63,602
5.07	Closing balance	1,279,584	-19,220	24,053	32,602	-	1,317,019	-	1,317,019

Consolidated Financial Statements / Statement of Changes in Equity - SCE - 01/01/2025 to 06/30/2025
(In thousands of reais)

.Account Code	Account Description	Paid-in capital	Capital reserves, options granted and treasury shares	Income reserves	Retained earnings (accumulated losses)	Other comprehensive income	Equity	Noncontrolling interests	Consolidated equity
5.01	Opening balances	981,773	-21,537	273,683	-	795	1,234,714	-	1,234,714
5.02	Prior-year adjustments	-	-	-	-	-	-	-	-
5.03	Adjusted opening balances	981,773	-21,537	273,683	-	795	1,234,714	-	1,234,714
5.04	Capital transactions with shareholders	50,238	1,372	-75,176	-26,500	-	-50,066	-	-50,066
5.04.01	Capital increase	50,238	-	-50,238	-	-	-	-	-
5.04.03	Recognized granted options	-	1,907	-	-	-	1,907	-	1,907
5.04.04	Treasury shares acquired	-	-1,780	-	-	-	-1,780	-	-1,780
5.04.06	Dividends	-	-	-24,938	-	-	-24,938	-	-24,938
5.04.07	Interest on equity	-	-	-	-26,500	-	-26,500	-	-26,500
5.04.08	Fair value of the Matching Shares Plan	-	2,534	-	-	-	2,534	-	2,534
5.04.09	Disposal/transfer of shares	-	-1,289	-	-	-	-1,289	-	-1,289
5.05	Total comprehensive income	-	-	-	50,556	-1,102	49,454	-	49,454
5.05.01	Net profit for the period	-	-	-	50,556	-	50,556	-	50,556
5.05.02	Other comprehensive income	-	-	-	-	-1,102	-1,102	-	-1,102
5.07	Closing balance	1,032,011	-20,165	198,507	24,056	-307	1,234,102		1,234,102

Consolidated Financial Statements / Statement of Value Added
(In thousands of reais)

Account Code	Account Description	Current YTD 01/01/2026 to 06/30/2026	Prior YTD 01/01/2025 to 06/30/2025
7.01	Revenue	3,470,344	3,058,008
7.01.01	Sales of goods, products and services	3,250,220	2,818,994
7.01.02	Other revenue	221,870	238,807
7.01.04	Reversal of/allowance for expected credit losses	-1,746	207
7.02	Inputs acquired from third parties	-2,453,387	-2,176,341
7.02.01	Cost of products, goods and services	-2,206,337	-1,965,251
7.02.02	Material, energy, services from third parties and other	-262,332	-222,529
7.02.03	Loss/Recovery of assets	15,282	11,439
7.03	Gross value added	1,016,957	881,667
7.04	Retentions	-124,449	-114,878
7.04.01	Depreciation, amortization and depletion	-124,449	-114,878
7.05	Net value added generated	892,508	766,789
7.06	Value added received in transfer	27,181	33,868
7.06.02	Finance income	27,181	33,868
7.07	Total value added distributable	919,689	800,657
7.08	Distribution of value added	919,689	800,657
7.08.01	Personnel	352,164	319,602
7.08.01.01	Direct Remuneration	292,400	258,098
7.08.01.02	Benefits	34,195	38,679
7.08.01.03	Severance Indemnity Fund (FGTS)	25,569	22,825
7.08.02	Taxes, charges and contributions	392,927	325,843
7.08.02.01	Federal	113,398	101,978
7.08.02.02	State	273,329	217,759
7.08.02.03	Local	6,200	6,106
7.08.03	Remuneration of third-party capital	110,996	104,656
7.08.03.01	Interest	88,772	85,629
7.08.03.02	Rent	22,224	19,027
7.08.04	Equity remuneration	63,602	50,556
7.08.04.01	Interest on Equity (IOE)	31,000	26,500
7.08.04.03	Retained Profits/Loss for the period	32,602	24,056

PanVel

A rotina que faz bem

Interim Financial Information

At June 30, 2026

Contents

Individual and consolidated financial statements

Notes to the individual and consolidated financial statements

Reports and representations

Dimed S.A. Distribuidora de Medicamentos

Balance sheet

June 30, 2026 and December 31, 2025

(In thousands of reais)

	Note	Individual		Consolidated	
		06/30/2026	12/31/2025	**06/30/2026**	12/31/2025
Assets					
Current					
Cash and cash equivalents	6	**59,265**	42,541	**59,995**	43,745
Short-term investments	6	**199,902**	376,761	**235,203**	386,751
Trade accounts receivable	7	**547,966**	567,462	**555,937**	574,182
Other accounts receivable		**89,816**	97,509	**90,324**	97,863
Inventories	8	**1,176,821**	1,142,616	**1,204,480**	1,166,554
Income tax and social contribution	9	**4,884**	3,560	**6,434**	5,124
Taxes recoverable	10	**25,199**	22,821	**27,015**	22,954
Other current assets		**5,475**	-	**5,475**	-
Properties available for sale		**-**	-	**414**	414
Total current assets		**2,109,328**	2,253,270	**2,185,277**	2,297,587
Noncurrent					
Deferred income tax and social contribution	14	**43,525**	50,254	**53,518**	59,949
Prepaid expenses		**708**	1,300	**708**	1,300
Taxes recoverable	10	**14,562**	14,465	**14,562**	14,465
Judicial deposits	21	**3,307**	4,205	**3,307**	4,205
Other assets		**1,640**	860	**1,640**	860
Equity interests	11	**78,222**	72,842	**-**	-
Other investments		**9,066**	8,253	**9,065**	8,253
Property, plant and equipment (PPE)	12	**576,324**	580,266	**589,664**	593,793
Property, plant and equipment (PPE) in operation	12	**37,107**	22,775	**37,107**	22,775
Right of use	20	**706,730**	718,797	**706,730**	718,797
Intangible assets	13	**106,850**	107,161	**108,311**	108,526
Total noncurrent assets		**1,578,041**	1,581,178	**1,524,612**	1,532,923
Total assets		**3,687,369**	3,834,448	**3,709,889**	3,830,510

	Note	Individual		Consolidated	
		06/30/2026	12/31/2025	**06/30/2026**	12/31/2025
Liabilities					
Current					
Payroll and related charges		**106,692**	84,088	**108,565**	85,488
Trade accounts payable	16	**653,887**	734,761	**642,328**	725,307
Trade accounts payable – forfaiting	16	**1,957**	-	**1,957**	-
Tax obligations	18	**79,162**	55,562	**83,598**	59,637
Loans and financing	17	**140,250**	185,960	**146,282**	191,815
Leases payable	20	**139,905**	136,889	**139,905**	136,889
Derivative financial instruments		**-**	5,354	**-**	5,354
Interest on equity	17	**48,270**	23,948	**48,270**	23,948
Profit sharing payable	19	**-**	18,190	**-**	18,401
Other liabilities		**65,656**	67,100	**67,491**	65,244
Other provisions		**11,406**	8,525	**11,480**	8,587
Payables to subsidiaries	30	**-**	27,000	**-**	-
Total current liabilities		**1,247,185**	1,347,377	**1,249,876**	1,320,670
Noncurrent					
Loans and financing	17	**449,254**	498,378	**468,072**	520,159
Leases payable	20	**649,491**	657,402	**649,491**	657,402
Interest on equity	17	**7,810**	34,070	**7,810**	34,070
Other obligations		**9,108**	8,735	**9,108**	8,735
Provision for contingencies	21	**7,502**	6,635	**8,513**	7,623
Total noncurrent liabilities		**1,123,165**	1,205,220	**1,142,994**	1,227,989
Equity	22				
Capital		**1,279,584**	1,212,695	**1,279,584**	1,212,695
Treasury shares		**(10,292)**	(21,359)	**(10,292)**	(21,359)
Goodwill reserve		**(13,024)**	(8,233)	**(13,024)**	(8,233)
Long-term incentive reserve		**4,096**	7,806	**4,096**	7,806
Income reserve		**24,053**	90,942	**24,053**	90,942
Retained earnings		**32,602**	-	**32,602**	-
Total equity		**1,317,019**	1,281,851	**1,317,019**	1,281,851
Total liabilities		**3,687,369**	3,834,448	**3,709,889**	3,830,510

The accompanying notes are an integral part of the individual and consolidated interim financial information.

Dimed S.A. Distribuidora de Medicamentos

grupo panvel

Statements of profit or loss
June 30, 2026 and 2025
(In thousands of reais)

		Quarter				Accumulated			
		Individual		Consolidated		Individual		Consolidated	
	Note	06/30/2026	06/30/2025	06/30/2026	06/30/2025	06/30/2026	06/30/2025	06/30/2026	06/30/2025
Gross sales of products and services	25	**1,631,015**	1,408,961	**1,635,294**	1,413,727	**3,186,614**	2,760,815	**3,206,107**	2,770,423
Sales taxes	25	**(107,653)**	(83,083)	**(108,721)**	(84,146)	**(208,991)**	(165,041)	**(213,096)**	(166,774)
Returns and unconditional discounts	25	**(16,884)**	(15,426)	**(17,423)**	(15,835)	**(33,272)**	(29,578)	**(34,200)**	(31,215)
Net revenue from sales and services	25	**1,506,478**	1,310,452	**1,509,150**	1,313,746	**2,944,351**	2,566,196	**2,958,811**	2,572,434
Cost of goods sold and services rendered	26	**(1,016,368)**	(879,258)	**(1,015,225)**	(880,241)	**(1,999,142)**	(1,737,207)	**(2,002,198)**	(1,737,834)
Gross profit		**490,110**	431,194	**493,925**	433,505	**945,209**	828,989	**956,613**	834,600
Selling expenses	27	**(374,853)**	(327,484)	**(376,995)**	(329,734)	**(723,135)**	(646,737)	**(727,318)**	(650,317)
General and administrative expenses	27	**(55,785)**	(47,127)	**(57,048)**	(48,438)	**(102,477)**	(88,878)	**(104,981)**	(91,304)
Other operating income (expenses), net	28	**6,376**	(167)	**6,597**	(238)	**10,124**	15,387	**10,332**	15,445
Equity pickup	11	**901**	(592)	**-**	-	**5,379**	1,322	**-**	-
		(423,361)	(375,370)	**(427,446)**	(378,410)	**(810,109)**	(718,906)	**(821,967)**	(726,176)
Operating income before finance income (costs)		**66,749**	55,824	**66,479**	55,095	**135,100**	110,083	**134,646**	108,424
Finance income (costs)									
Finance income	29	**8,354**	9,793	**9,662**	10,668	**23,666**	27,430	**26,093**	30,158
Finance costs	29	**(40,295)**	(38,142)	**(40,782)**	(38,157)	**(87,282)**	(81,125)	**(88,204)**	(81,704)
		(31,941)	(28,349)	**(31,120)**	(27,489)	**(63,616)**	(53,695)	**(62,111)**	(51,546)
Income before income and social contribution taxes		**34,808**	27,475	**35,359**	27,606	**71,484**	56,388	**72,535**	56,878
Income and social contribution taxes									
Current	15	**(602)**	609	**(1,349)**	(49)	**(1,153)**	(3,302)	**(2,501)**	(5,042)
Deferred	15	**(3,835)**	(2,994)	**(3,639)**	(2,467)	**(6,729)**	(2,530)	**(6,432)**	(1,280)
		(4,437)	(2,385)	**(4,988)**	(2,516)	**(7,882)**	(5,832)	**(8,933)**	(6,322)
Net income for the period		**30,371**	25,090	**30,371**	25,090	**63,602**	50,556	**63,602**	50,556
Basic earnings per common share		**0.21**	0.17	**0.21**	0.17	**0.43**	0.34	**0.43**	0.34
Diluted earnings per common share		**0.20**	0.17	**0.20**	0.17	**0.42**	0.34	**0.42**	0.34

The accompanying notes are an integral part of the individual and consolidated interim financial information.

Dimed S.A. Distribuidora de Medicamentos

Statements of comprehensive income
June 30, 2026 and 2025
(In thousands of reais)

	Quarter				Accumulated			
	Individual		Consolidated		Individual		Consolidated	
	06/30/2026	06/30/2025	**06/30/2026**	06/30/2025	**06/30/2026**	06/30/2025	**06/30/2026**	06/30/2025
Net income for the period	**30,371**	25,090	**30,371**	25,090	**63,602**	50,556	**63,602**	50,556
Other comprehensive income	**-**	(427)	**-**	(427)	**-**	(307)	**-**	(307)
Total comprehensive income for the period	**30,371**	24,663	**30,371**	24,663	**63,602**	50,249	**63,602**	50,249

The accompanying notes are an integral part of the individual and consolidated interim financial information.

Dimed S.A. Distribuidora de Medicamentos

Statements of changes in equity

June 30, 2026 and 2025
(In thousands of reais)

	Capital	Treasury shares	Capital reserve - stock option plan	Income reserve				Retained earnings	Other comprehensive income	Total
				Tax incentives	Legal reserve	For capital increase	Proposed additional dividends and interest on equity			
Balances at December 31, 2024	981,773	(23,993)	2,456	180,684	17,823	50,238	24,938	-	795	1,234,714
Capital increase	50,238	-	-	-	-	(50,238)	-	-	-	-
Acquisition of own shares	-	(1,780)	-	-	-	-	-	-	-	(1,780)
Dividends	-	-	-	-	-	-	(24,938)	-	-	(24,938)
Recognized stock options granted	-	3,697	(1,790)	-	-	-	-	-	-	1,907
Disposal/transfer of shares	-	6,698	(7,987)	-	-	-	-	-	-	(1,289)
Proposed interest on equity (IOE)	-	-	-	-	-	-	-	(26,500)	-	(26,500)
Fair value of matching share plan	-	-	2,534	-	-	-	-	-	-	2,534
Net income for the period	-	-	-	-	-	-	-	50,556	-	50,556
Other comprehensive income	-	-	-	-	-	-	-	-	(1,102)	(1,102)
Balances at June 30, 2025	1,032,011	(15,378)	(4,787)	180,684	17,823	-	-	24,056	(307)	1,234,102
Balances at December 31, 2025	1,212,695	(21,359)	(427)	-	24,053	66,889	-	-	-	1,281,851
Capital increase	**66,889**	**-**	**-**	**-**	**-**	**(66,889)**	**-**	**-**	**-**	**-**
Acquisition of own shares	**-**	**(2,137)**	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**(2,137)**
Recognized stock options granted	**-**	**5,463**	**(1,269)**	**-**	**-**	**-**	**-**	**-**	**-**	**4,194**
Disposal/transfer of shares	**-**	**7,741**	**(10,244)**	**-**	**-**	**-**	**-**	**-**	**-**	**(2,503)**
Interest on equity	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**(31,000)**	**-**	**(31,000)**
Fair value of matching share plan	**-**	**-**	**3,012**	**-**	**-**	**-**	**-**	**-**	**-**	**3,012**
Net income for the period	**-**	**-**	**-**	**-**	**-**	**-**	**-**	**63,602**	**-**	**63,602**
Balances at June 30, 2026	**1,279,584**	**(10,292)**	**(8,928)**	**-**	**24,053**	**-**	**-**	**32,602**	**-**	**1,317,019**

The accompanying notes are an integral part of the individual and consolidated interim financial information.

Dimed S.A. Distribuidora de Medicamentos

grupo panvel

Statements of cash flows
June 30, 2026 and 2025
(In thousands of reais)

	Note	Individual		Consolidated	
		06/30/2026	06/30/2025	**06/30/2026**	06/30/2025
Cash flows from operating activities					
Net income for the year		**63,602**	50,556	**63,602**	50,556
Adjustments:					
Depreciation/amortization of property, plant and equipment and intangible assets	12, 13 and 20	**123,667**	114,095	**124,453**	114,878
Provision for contingent liabilities	21	**867**	468	**890**	557
Equity pickup	11	**(5,379)**	(1,322)	**-**	-
Cost of property, plant and equipment and intangible assets written off	12 and 13	**1,655**	504	**1,697**	556
Allowance for expected credit losses	7	**1,747**	(207)	**1,747**	(207)
Provision for inventory losses	8	**(23)**	47	**22**	217
Stock option plan or share subscription		**3,012**	2,534	**3,012**	2,534
Deferred income and social contribution taxes	15	**6,729**	2,530	**6,432**	1,280
Current income tax and social contribution	15	**1,153**	3,302	**2,501**	5,042
Interest on loans and financing		**31,670**	11,454	**32,351**	11,657
Interest expenses on leases	20	**39,940**	34,162	**39,940**	34,162
Recognition of borrowing costs	17	**1,010**	-	**1,010**	-
Income from short-term investments	29	**(17,055)**	(6,526)	**(19,499)**	(9,595)
Exchange gains (losses) on short-term investments		**281**	-	**281**	-
Proceeds from the sale of property, plant and equipment		**-**	-	**(2,924)**	-
Receipts from the sale of property, plant and equipment		**-**	-	**3,000**	-
Changes in assets and liabilities					
Trade accounts receivable	7	**17,749**	(12,848)	**16,498**	(12,901)
Inventories	8	**(34,182)**	63,191	**(37,948)**	62,962
Trade accounts payable	16	**(80,874)**	(28,873)	**(82,979)**	(30,603)
Trade accounts payable – forfaiting	16	**1,957**	-	**1,957**	-
Income and social contribution taxes payable		**47,167**	4,158	**49,139**	6,677
Judicial deposits	21	**898**	(34)	**898**	(34)
Income tax and social contribution paid		**(963)**	(5,615)	**(2,101)**	(7,911)
Taxes recoverable		**(4,952)**	393	**(7,970)**	(1,518)
Other asset groups		**1,216**	25,551	**1,064**	26,415
Other liability groups		**(31,344)**	(32,709)	**(27,874)**	(33,436)
Net cash flows from operating activities		**169,548**	224,811	**169,199**	221,288
Cash flows from investing activities					
Acquisition of property, plant and equipment	12	**(45,845)**	(48,776)	**(46,406)**	(50,161)
Acquisition of intangible assets	13	**(14,875)**	(18,145)	**(15,127)**	(18,473)
Short-term investments		**(123,507)**	(133,837)	**(162,080)**	(145,201)
Redemption of short-term investments		**317,140**	81,159	**332,846**	141,824
Net cash flows from investing activities		**132,913**	(119,599)	**109,233**	(72,011)
Cash flows from financing activities					
Payment of interest on equity	17	**(28,799)**	(26,233)	**(28,799)**	(26,233)
Acquisition of own shares		**(2,137)**	(1,780)	**(2,137)**	(1,780)
Loans/financing (principal) taken out	17	**-**	90,000	**-**	95,342
Payment of leases (principal)	17	**(66,797)**	(65,529)	**(66,797)**	(65,529)
Payment of interest on leases	17	**(39,940)**	(34,162)	**(39,940)**	(34,162)
Repayment of principal - financing	17	**(90,000)**	(120,000)	**(92,740)**	(120,000)
Payment of interest - financing	17	**(37,345)**	(31,107)	**(38,241)**	(31,150)
Shares granted - Matching Share plan		**6,472**	1,907	**6,472**	1,907
Intragroup loans		**(27,000)**	50,000	**-**	-
Interest paid on intragroup loans		**(191)**	-	**-**	-
Net cash flows from financing activities		**(285,737)**	(136,904)	**(262,182)**	(181,605)
Net increase (decrease) in cash and cash equivalents		**16,724**	(31,692)	**16,250**	(32,328)
Cash and cash equivalents at beginning of period		**42,541**	78,903	**43,745**	79,995
Cash and cash equivalents at end of period		**59,265**	47,211	**59,995**	47,667
Net increase (decrease) in cash and cash equivalents		**16,724**	(31,692)	**16,250**	(32,328)

The accompanying notes are an integral part of the individual and consolidated interim financial information.

grupo panvel

Statements of value added

June 30, 2026 and 2025
(In thousands of reais)

	Quarter				Accumulated			
	Individual		Consolidated		Individual		Consolidated	
	06/30/2026	06/30/2025	**06/30/2026**	06/30/2025	**06/30/2026**	06/30/2025	**06/30/2026**	06/30/2025
Revenues	**1,722,103**	1,510,701	**1,774,331**	1,559,164	**3,373,466**	2,970,100	**3,470,344**	3,058,008
Sales of goods, products and services	**1,614,131**	1,393,535	**1,666,368**	1,442,027	**3,153,343**	2,731,237	**3,250,220**	2,818,994
Other revenues	**108,884**	117,070	**108,875**	117,041	**221,869**	238,656	**221,870**	238,807
Allowance for expected credit losses	**(912)**	96	**(912)**	96	**(1,746)**	207	**(1,746)**	207
Bought-in inputs	**(1,206,499)**	(1,071,467)	**(1,255,306)**	(1,118,751)	**(2,368,770)**	(2,092,294)	**(2,453,387)**	(2,176,341)
Cost of goods and products sold and services rendered	**(1,081,140)**	(960,643)	**(1,128,219)**	(1,005,512)	**(2,125,502)**	(1,885,359)	**(2,206,337)**	(1,965,251)
Materials, energy, third-party services and other	**(138,330)**	(109,628)	**(140,234)**	(111,816)	**(258,521)**	(218,670)	**(262,332)**	(222,529)
Loss/recovery of assets	**12,971**	(1,196)	**13,147**	(1,423)	**15,253**	11,735	**15,282**	11,439
Gross value added	**515,604**	439,234	**519,025**	440,413	**1,004,696**	877,806	**1,016,957**	881,667
Depreciation and amortization	**(62,001)**	(57,653)	**(62,395)**	(58,045)	**(123,667)**	(114,095)	**(124,449)**	(114,878)
Net value added produced by the entity	**453,603**	381,581	**456,630**	382,368	**881,029**	763,711	**892,508**	766,789
Value added received in transfer	**9,589**	9,553	**10,035**	12,824	**29,897**	29,448	**27,181**	33,868
Equity pickup	**901**	(592)	**-**	-	**5,379**	1,322	**-**	-
Finance income	**8,688**	10,145	**10,035**	12,824	**24,518**	28,126	**27,181**	33,868
Total value added to be distributed	**463,192**	391,134	**466,665**	395,192	**910,926**	793,159	**919,689**	800,657
Distribution of value added	**463,192**	391,134	**466,665**	395,192	**910,926**	793,159	**919,689**	800,657
Personnel	**183,197**	164,572	**184,118**	165,372	**350,437**	318,283	**352,164**	319,602
Direct compensation	**155,820**	129,870	**156,589**	130,510	**290,953**	257,055	**292,400**	258,098
Benefits	**14,869**	23,000	**14,951**	23,108	**34,036**	38,487	**34,195**	38,679
Severance Pay Fund (FGTS)	**12,508**	11,702	**12,578**	11,754	**25,448**	22,741	**25,569**	22,825
Taxes, charges and contributions	**197,482**	153,235	**199,482**	154,829	**387,050**	322,929	**392,927**	325,843
Federal	**54,560**	48,535	**56,058**	49,650	**109,063**	99,843	**113,398**	101,978
State	**140,027**	101,853	**140,371**	102,188	**272,076**	217,262	**273,329**	217,759
Local	**2,895**	2,847	**3,053**	2,991	**5,911**	5,824	**6,200**	6,106

Statements of value added
June 30, 2026 and 2025
(In thousands of reais)

	Quarter				Accumulated			
	Individual		Consolidated		Individual		Consolidated	
	06/30/2026	06/30/2025	**06/30/2026**	06/30/2025	**06/30/2026**	06/30/2025	**06/30/2026**	06/30/2025
Debt remuneration	**52,142**	48,237	**52,694**	49,901	**109,837**	101,391	**110,996**	104,656
Interest	**40,487**	38,670	**41,003**	40,451	**87,639**	82,112	**88,772**	85,629
Rent	**11,655**	9,567	**11,691**	9,450	**22,198**	19,279	**22,224**	19,027
Equity remuneration	**30,371**	25,090	**30,371**	25,090	**63,602**	50,556	**63,602**	50,556
Interest on equity	**18,000**	13,500	**18,000**	13,500	**31,000**	26,500	**31,000**	26,500
Retained earnings	**12,371**	11,590	**12,371**	11,590	**32,602**	24,056	**32,602**	24,056

The accompanying notes are an integral part of the individual and consolidated interim financial information.

1. Operations

1.1 Operations

Dimed S.A. Distribuidora de Medicamentos or “Dimed” and its subsidiaries (jointly referred to as the “Company”), with head office in the city of Eldorado do Sul, state of Rio Grande do Sul, is primarily engaged in the sale of medicines, perfumery, personal care and beauty products, cosmetics and dermo-cosmetics, operating in the pharmaceutical retail industry. To support retail sales, the Company has distribution centers in the states of Rio Grande do Sul, Paraná, and Espírito Santo. There are also 664 stores distributed among the states of Rio Grande do Sul (421 stores), Santa Catarina (103 stores), Paraná (125 stores), and São Paulo (15 stores). In the 12-month period, the Company opened a total of 31 stores, 7 of which in the second quarter of 2026. In this quarter, there was also the transfer of 1 branch.

The parent company is a corporation listed on B3 S.A. - BRASIL, BOLSA, BALCÃO (“PNVL3”).

Subsidiary Laboratório Industrial Farmacêutico Lifar Ltda. operates in the industrial segment, producing a wide range of products in the cosmetics, food, medicine and outsourced production segments. Such subsidiary is responsible for the production of the own brand and third-party product lines. It is the parent company of Empresa Lifar Distribuidora de Produtos Farmacêuticos Ltda., which is engaged in the distribution of the manufactured products.

Subsidiary Dimesul Gestão Imobiliária Ltda. is engaged in centralizing and optimizing the management of own and third-party properties, as well as contributing to the performance of marketplace activities.

1.2 Authorization for issue of the quarterly information

The issue of this individual and consolidated interim financial information was authorized by the Company’s Board of Directors on August 6, 2026.

2. Summary of accounting policies

Accounting policies used in preparing these individual and consolidated interim financial statements are listed in the subitems described below. These policies have been consistently applied for all years presented.

2.1 Basis of preparation and presentation of individual and consolidated interim financial statements

The Company's individual and consolidated interim financial statements, contained in the Quarterly Information Form (ITR), for the quarter ended June 30, 2026, have been prepared and are being presented in accordance with technical pronouncement CPC 21 (R1) - Interim Financial Reporting and in accordance with the international standard IAS 34 - "Interim Financial Reporting", issued by the International Accounting Standards Board (IASB), and presented in accordance with the rules issued by the Brazilian Securities and Exchange Commission (CVM), applied in these quarterly financial statements.

Company’s Management understands that all significant information related to the interim financial statements is disclosed and corresponds to the information used to manage the Company’s operations.

(In thousands of reais)

The interim financial statements were prepared by the Company to update the users on the relevant information presented for the period and should be analyzed together with the whole financial statements for the year ended December 31, 2025.

The preparation of interim financial statements is based on historical cost, except for financial instruments measured at fair value, as per Note 5, which require the use of certain accounting estimates that affect the balances of asset, liability and profit or loss accounts, as well as the exercise of judgment by management members in the process of applying the Company's accounting policies. The most significant effects on the book accounts that involve the use of estimates or that require more complex judgments are disclosed in Note 3.

In preparing these interim financial statements, the Company followed the same accounting policies and calculation methods applied in the individual and consolidated financial statements as at December 31, 2025. The Company adopted all standards, revised standards and interpretations issued by CPC and IASB applicable to reporting periods beginning on or after January 1, 2026 and effective at the end of the reporting period.

The presentation of the individual and consolidated Statement of Value Added (DVA) is required by the Brazilian Corporate Law and by the accounting practices adopted in Brazil applicable to publicly-held companies, and this statement has been prepared in accordance with CPC 09 – Statement of Value Added. The Statement of Value Added is not required under the IFRS Accounting Standards. As such, for IFRS Accounting Standards purposes, this statement is presented as supplementary information.

2.1.1 Consolidated interim financial statements

The consolidated interim financial statements include the operations of the Company and of the following subsidiaries:

		Direct equity interest	
Company	**Activity**	**2026**	**2025**
Dimesul Gestão Imobiliária Ltda.	Management and administration of own and/or third-party properties and operation of marketplace activities.	**99.99%**	99.99%
Laboratório Industrial Farmacêutico Lifar Ltda.	Production of cosmetics, food, medicines and outsourced production.	**99.99%**	99.99%

		Indirect equity interest	
Company	**Activity**	**2026**	**2025**
Lifar Distribuidora de Produtos Farmacêuticos Ltda.	Pharmaceutical products distributor.	**99.97%**	99.97%

These consolidated interim financial statements are prepared in accordance with the consolidation practices and applicable legal provisions. The accounting practices adopted by the Subsidiaries were consistently applied and are consistent with the ones adopted by the Company. Where applicable, all transactions, balances, revenues and expenses between the Subsidiaries and the Company are fully eliminated from the consolidated interim financial statements.

The interim financial statement period of the Subsidiaries included in the consolidation coincides with that of the Parent Company and the accounting policies have been consistently applied in the consolidated companies and are consistent with those used in the prior year.

Income for the year is fully attributed to the controlling shareholders given that equity interest held by non-controlling shareholders corresponds to 0.01% of the consolidated.

2.2 New accounting standards and interpretations

2.2.1 IFRS S1/CBPS 01 – General requirements for disclosure of sustainability-related financial information and IFRS S2/CBPS 02 - Climate-related disclosures

The standards establish guidelines for the disclosure of sustainability and climate-related information, including risks and opportunities relevant to users of financial statements.
In May 2026, the CVM published CVM Resolution No. 244/2026, which amended CVM Resolution No. 193/2023 and revoked the mandatory disclosure of sustainability-related financial information, adopting the "comply or explain" model. Therefore, the Company continues to monitor regulatory developments related to this issue and assess their potential impacts on governance processes, internal controls, and corporate reporting. To date, the Company does not expect to adopt the disclosures required by IFRS S1/CBPS 01 and IFRS S2/CBPS 02 for the next reporting cycle.

2.2.2 CPC 51/IFRS 18 – Presentation and Disclosure in Financial Statements

The standard will come into effect on January 1, 2027, and is set to replace IAS 1/CPC 26 – Presentation of Financial Statements, introducing significant amendments to the structure and presentation of financial statements. The main amendments notably include the creation of new categories for the Statement of Profit or Loss, such as operating, investing and financing, besides requiring new subtotals for the classification of revenues and expenses. These amendments aim to improve the comparability and transparency of the financial information disclosed by entities.

The Company elected not to early adopt the standard and concluded that its application is not expected to affect the recognition and measurement criteria currently applied, being limited to the presentation of the financial statements. CPC 51/IFRS 18 will be implemented within the timeframe established by the regulatory authorities, in compliance with the transition requirements set forth in the standard.

2.2.3 IFRS 19 – Subsidiaries without Public Accountability

The new standard is effective for reporting periods beginning on or after January 1, 2027, with the objective of simplifying the process of consolidating financial statements, allowing the adoption of uniform accounting policies between the parent and subsidiary, the standard facilitates the presentation of financial reports within business groups, making them more consistent and compatible. The Company did not identify any material impacts.

2.2.4 Brazilian Tax System Reform

The implementation will take place gradually, with a transition period between 2026 and 2032, highlighting the replacement of consumption taxes (PIS, COFINS, ICMS, ISS, and IPI) with two new taxes: Contribution on Goods and Services (CBS), under federal jurisdiction, and Tax on Goods and Services (IBS), under state and municipal jurisdictions. For 2026, IBS and CBS taxes will be indicated in invoices for information purposes.

The Company has been continuously monitoring the related developments through the support of specialized tax advisors and, during the transition period, will adopt some measures such as adjusting the ERP systems and internal controls to reflect the new legislation, as well as providing training to internal teams.

In 2026, CBS and IBS taxes are being indicated in invoices for information purposes only, without any financial effects. Management has assessed the possible impacts of such tax reform and does not expect any material impact on the interim financial statements for the period ended June 30, 2026.

2.2.5 Amendments to IFRS 9 and IFRS 7 – Classification and Measurement of Financial Instruments

The IASB issued amendments to IFRS 9 – Financial Instruments and IFRS 7 – Financial Instruments: Disclosures that became effective beginning January 1, 2026, with a view to improving certain aspects related to the classification, measurement, and disclosure of financial assets, including clarifications applicable to financial instruments with specific contractual characteristics.

Management has assessed the relevant effects and concluded that their adoption did not materially affect the Company's interim financial statements.

2.2.6 Annual Improvements to IFRS Accounting Standards – Volume 11

The IASB issued specific adjustments aimed at clarifying wording, correcting inconsistencies, and enhancing the coherence of various accounting standards. The improvements encompass five standards: IFRS 1, IFRS 7, IFRS 9, IFRS10 and IAS 7.

The amendments are effective for annual reporting periods beginning on or after January 1, 2026, with early adoption being permitted. The Company has assessed the effects of such improvements and concluded that the interim financial statements will not be materially affected.

3. Critical accounting estimates and judgments

In preparing the individual and consolidated interim financial information, the Company uses estimates and judgments to account for certain assets, liabilities and other transactions.

Therefore, the individual and consolidated interim financial information includes various estimates referring to the allowance for doubtful accounts, provision for inventory losses, assessment of the useful lives of property, plant and equipment, fair value measurement of financial instruments, contractual payments, provisions for civil, labor and tax risks, discount rate on leases, share-based payments and certain provisions for income taxes. These judgments, estimates and assumptions are reviewed at each reporting period.

There were no changes in the methods used to calculate the estimates compared to the prior year. Therefore, as permitted by IAS 34/CPC 21 (R1) – Interim Financial Reporting, Management elected not to disclose in detail the significant accounting judgments, estimates and assumptions made by the Company. Therefore, this individual and consolidated interim financial information should be read in conjunction with the individual and consolidated annual financial statements for the year ended December 31, 2025.

4. Financial risk management

4.1 Financial risk factors

The Company's activities expose it to financial risks such as: market risk (including fair value interest rate risk and cash flow interest rate risk), credit risk, liquidity risk and currency risk. The Company's global risk management program is concentrated in the unpredictability of the financial markets and aims to minimize potential adverse effects on the Company's financial performance.

The Company manages financial risks by identifying and continuously assessing potential exposures, adopting risk mitigation measures in alignment with the operational areas. The Executive Board sets out the principles for overall risk management, covering aspects such as interest rate risk, credit risk, use of financial instruments, and investment of surplus cash.

4.1.1 Market risk

Interest rate risk

The Company's interest rate risk arises from long-term borrowings and cash surplus invested in floating rate notes, such as Bank Deposit Certificates (CDB). Borrowings and investments at variable rates expose the Company to the cash flow interest rate risk. Borrowings and investments issued at fixed rates expose the Company to the fair value interest rate risk. As at June 30, 2026, the Company's borrowings and investments at variable and fixed rates were accounted for in Brazilian reais.

The Company analyzes its exposure to interest rate in a dynamic manner. Scenarios are simulated, taking into consideration the refinancing, renewal of existing positions and alternative financing, as well as new investment possibilities for cash surplus. Based on these scenarios, the Company defines a reasonable interest rate change and calculates its impact on profit or loss. The scenarios are prepared only for liabilities and assets representing key interest-bearing positions.

Currency risk

As part of its financial management strategy, the Company also conducts external funding in the 4131 format, structured with derivative financial instruments, with the objective of fully mitigating exposure to exchange rate variation. These operations provide greater financial stability, cash flexibility, and optimization of the cost of funding. The use of derivatives seeks to ensure that the effects of exchange rate volatility do not have an unfavorable impact on the Company's results.

Under CPC 48 (IFRS 9), derivatives involving assets or liabilities measured at fair value were recognized during the effective period of those transactions. In the first quarter of 2026, these transactions were fully settled and the exchange gains (losses) on debts and derivatives were offset in financial terms, eliminating the exposure to currency risks underlying those borrowings.

(In thousands of reais)

The Company has made foreign short-term investments using own cash so as to mitigate the exposure to foreign exchange fluctuations underlying foreign currency-denominated commitments. Maintaining assets in the same currency contributes to the alignment between assets and liabilities, reducing the effects of foreign exchange fluctuations on finance income (costs) and supporting more efficient liquidity management.

Sensitivity analysis

The Company's results are susceptible to variations in interest rates which apply to short-term investments, loans and financing with variable interest rates, mainly related to CDI.

For assets and liabilities exposed to interest rates (CDI), the sensitivity analysis is prepared assuming that the open amount of liabilities as at the reporting date was open during the entire period. Scenario I is based on the interest curve of CDI, accumulated in the period that represents the sum of daily interest projected for the following 12 months, considering the expectations of the Central Bank for the benchmark rates effective on the base date of the projection and is used to internally report the interest rate risk to key Management personnel and represents the Executive Board's assessment of the reasonably possible change in interest rates.

In addition, exclusively for sensitivity analysis purposes, and in order to measure any effects on finance income (costs), additional scenarios were prepared, considering a 25% positive and negative variation in the impact calculated under Scenario I, equivalent to 357 basis points, assuming that other variables remained constant, the financial income for the period would increase and decrease by R$1.7 million.

Index/Operation	Scenario I	Increase in interest +25%	Decrease in interest -25%
		Scenario II	Scenario III
Short-term investments + cash and cash equivalents	34,852	43,565	26,139
Debt – CDI	(41,819)	(52,273)	(31,364)
Effect on financial income	(6,967)	(8,709)	(5,225)

The Company has financing operations contracted at fixed rate, Benchmark Rate plus fixed rate, and CDI plus fixed rate. For sensitivity analysis purposes, only exposure to CDI rate fluctuation was considered, as this is the main market risk factor with potential impact on the Company's results and cash flows. Installments contracted at fixed rates are not subject to market rate fluctuations and, therefore, were not considered in the scenarios presented.

For sensitivity analysis purposes solely, the Executive Board assessed a 25% increase/decrease in foreign exchange rates.

	Notional (R$)	US$	US$ increase +25%	US$ decrease -25%
Index/Operation	06/30/2026	Stable	Scenario I	Scenario II
US dollar (US$)		5.17	6.47	3.88
Time Deposit	31,525	-	(7,881)	7,881
Effects of exchange differences	**-**	**-**	**(7,881)**	**7,881**

(In thousands of reais)

4.1.2 Credit risk

Credit risk is managed on a corporate-level basis and arises from cash and cash equivalents, as well as credit exposures with customers, both legal entities and individuals, including outstanding receivables. For banks and financial institutions, only notes of entities that have compensating transactions with the Company are accepted. The credit analysis area assesses the customer creditworthiness, taking into consideration its financial position, past experience and other factors. Individual risk limits are established based on internal or external ratings, according to the limits determined by the Board of Directors and the Executive Board. The use of credit limits is regularly monitored by the Executive Board. Sales to customers of retail branches are settled in local currency, bank transfer, agreements or by means of the main credit cards existing in the market.

The carrying amount of financial assets represents the maximum credit risk exposure. Cash flow projection is carried out based on information provided by the operating units. The Company monitors the forecasts of the Company's liquidity requirements to ensure that it has sufficient cash to meet its operating needs. It also keeps sufficient margin of credit facilities, under repurchase agreements, available for the Company at any time, so that it does not exceed limits or breach loan agreement clauses (where applicable) in any of its credit facilities. Such projection takes into consideration the Company's debt financing plans, covenant compliance, compliance with internal ratio targets of the statement of financial position and, if applicable, external regulatory or legal requirements - for instance, currency restrictions.

4.1.3 Liquidity risk

Any cash surplus, in addition to the amount required for working capital management purposes, is invested in short-term investments, choosing instruments with appropriate maturities or sufficient liquidity to provide sufficient margins as determined by the above-mentioned forecasts. As at June 30, 2026, the Company had short-term investments amounting to R$199,902 in individual and R$235,203 in consolidated, which generated cash inflows to manage liquidity risk.
The table below presents the Company's non-derivative financial liabilities, by maturity date, corresponding to the remaining period in the statement of financial position up to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows.

	Consolidated				
As at June 30, 2026	**Contractual cash flow**	**Less than one year**	**1 to 3 years**	**3 to 5 years**	**More than 5 years**
Trade accounts payable	**644,285**	**644,285**	**-**	**-**	**-**
Leases	**1,074,686**	**216,652**	**373,528**	**253,353**	**231,153**
Loans and financing	**786,349**	**191,902**	**339,304**	**174,071**	**81,072**
Total	**2,505,320**	**1,052,839**	**712,832**	**427,424**	**312,225**

(In thousands of reais)

	Consolidated				
As at December 31, 2025	Contractual cash flow	Less than one year	1 to 3 years	3 to 5 years	More than five years
Trade accounts payable	725,307	725,307	-	-	-
Leases	794,291	136,889	194,135	288,927	174,340
Loans and financing	907,898	247,067	396,927	182,676	81,228
Total	2,427,496	1,109,263	591,062	471,603	255,568

4.2 Capital management

The Company's objectives in managing its capital are to safeguard its ability to continue as a going concern in order to provide return for its shareholders and benefits for other stakeholders, in addition to maintaining an optimal target capital structure to reduce the cost of capital.

To maintain or adjust its capital structure, the Company may revise the policy for payment of dividends, return capital to shareholders, issue new shares, or sell assets to reduce its indebtedness, for instance. In line with other companies in the sector, the Company monitors capital based on the financial leverage ratio. This ratio corresponds to the net debt divided by total capital. Net debt corresponds to total loans (including short and long-term loans, as stated in the consolidated statement of financial position), deducted from cash and cash equivalents. Total capital is calculated through the sum of equity, as stated in the consolidated statement of financial position, plus net debt.

The Company's business strategy is to maintain its net financial indebtedness, compared to the sum of net financial debt and equity, at low levels. Financial leverage ratios as at June 30, 2026 and December 31, 2025 are summarized as follows:

	Individual		Consolidated	
	06/30/2026	12/31/2025	**06/30/2026**	12/31/2025
Total loans (Note 17)	**589,504**	684,338	**614,354**	711,974
Less:				
Cash and cash equivalents (Note 6)	**(59,265)**	(42,541)	**(59,995)**	(43,745)
Short-term investments in local currency	**(168,377)**	(362,017)	**(203,678)**	(372,007)
Short-term investments in foreign currency	**(31,525)**	(14,744)	**(31,525)**	(14,744)
Net debt – A	**330,337**	265,036	**319,156**	281,478
Total equity	**1,317,019**	1,281,851	**1,317,019**	1,281,851
Total capital – B	**1,647,356**	1,546,887	**1,636,175**	1,563,329
Ratio - % - A/B	**20.05**	17.13	**19.51**	18.01

(In thousands of reais)

5. Financial instruments by category

5.1 Classification of financial assets

Financial assets are classified according to the table below as at June 30, 2026 and December 31, 2025:

	06/30/2026			
	Individual		**Consolidated**	
	Amortized cost	**Fair value through profit or loss**	**Amortized cost**	**Fair value through profit or loss**
Cash and cash equivalents	**-**	**59,265**	**-**	**59,995**
Short-term investments in local currency	**-**	**168,377**	**-**	**203,678**
Short-term investments in foreign currency	**-**	**31,525**	**-**	**31,525**
Trade accounts receivable and other receivables	**637,782**	**-**	**646,261**	**-**
Total	**637,782**	**259,167**	**646,261**	**295,198**

	12/31/2025			
	Individual		Consolidated	
	Amortized cost	Fair value through profit or loss	Amortized cost	Fair value through profit or loss
Cash and cash equivalents	-	42,541	-	43,745
Short-term investments in local currency	-	362,017	-	372,007
Short-term investments in foreign currency	-	14,744		14,744
Trade accounts receivable and other receivables	664,971	-	672,045	-
Total	664,971	419,302	672,045	430,496

5.2 Classification of financial liabilities

	06/30/2026			
	Individual		**Consolidated**	
	Amortized cost	**Fair value through profit or loss**	**Amortized cost**	**Fair value through profit or loss**
Trade accounts payable	**655,844**	**-**	**644,285**	**-**
Loans and financing	**589,504**	**-**	**614,354**	**-**
Lease obligations	**789,396**	**-**	**789,396**	**-**
Total	**2,034,744**	**-**	**2,048,035**	**-**

(In thousands of reais)

	12/31/2025			
	Individual		Consolidated	
	Amortized cost	Fair value through profit or loss	Amortized cost	Fair value through profit or loss
Trade accounts payable	734,761	-	725,307	-
Loans and financing	684,338	-	711,974	-
Lease obligations	794,291	-	794,291	-
Derivative financial instruments	-	5,354	-	5,354
Debts with related parties	27,000	-	-	-
Total	2,240,390	5,354	2,231,572	5,354

Fair values are determined based on market price quotations, when available, or in their absence, the present value of expected cash flows. The fair values of cash and cash equivalents, trade and other accounts receivable, and trade accounts payable are equivalent to their carrying amounts.

The estimated fair value for the Parent Company's loans and financing as at June 30, 2026 was R$406,176 and R$427,579 on a consolidated basis, calculated at prevailing market rates, considering nature, term and risks and can be compared with the book value of R$589,504 on the parent company and R$614,354 on the consolidated.

5.3 Fair value hierarchy

The Company applies technical pronouncement CPC 40 (R1) for financial instruments, which requires the disclosure of fair value measurements based on the following hierarchy levels:
Level 1: prices quoted (unadjusted) in active markets for identical assets or liabilities.
Level 2: other techniques for which all inputs that have a material effect on the recorded fair value are observable, either directly or indirectly.
Level 3: techniques using inputs that have a material effect on the fair value recorded that are not based on observable market data.
The Company’s financial instruments are measured using the Level 2 valuation technique. There were no transfers between levels 1, 2 and 3 until June 30, 2026.

6. Cash and cash equivalents and marketable securities

6.1 Cash and cash equivalents

		Individual		**Consolidated**	
	Average rate (p.a.)	**06/30/2026**	12/31/2025	**06/30/2026**	12/31/2025
Cash on hand (retail branches)	-	**5,470**	5,155	**5,470**	5,155
Short-term bank deposits	-	**1,912**	14,086	**2,642**	15,290
Short-term investments – fixed income (*)	95.3% of CDI	**51,883**	23,300	**51,883**	23,300
Total		**59,265**	42,541	**59,995**	43,745

(*) Short-term investments mostly refer to Bank Deposit Certificates (CBD) and repurchase agreements, remunerated at a CDI percentage. Information on investment liquidity is detailed in Note 4.

(In thousands of reais)

6.2 Marketable securities

	Average rate (p.a.)	Individual		Consolidated	
		06/30/2026	12/31/2025	**06/30/2026**	12/31/2025
Exclusive investment fund	102.2% of CDI	**168,377**	362,017	**203,633**	363,884
Bradesco referenced fund	105.5% of CDI	**-**	-	**45**	8,123
Total		**168,377**	362,017	**203,678**	372,007
Short-term investments in foreign currency*	4.3% (*)	**31,525**	14,744	**31,525**	14,744
Total		**199,902**	376,761	**235,203**	386,751

(*) Fixed rate.

The exclusive investment fund GD FIM Crédito Privado is a private credit fixed income fund under the management, administration and custody of BRAM – Bradesco Asset Management S.A. DTVM. The investment fund does not have significant financial obligations. These are limited to asset management fees, custody fees, audit fees and expenses. The fund is exclusively for the benefit of the Company and, therefore, the financial investment in the investment fund in which the Company holds an exclusive interest has been consolidated.
Short-term investments in local currency by type are broken down as follows:

	Consolidated	
Type	**06/30/2026**	12/31/2025
Investment funds	**72,710**	197,708
Financial Treasury Bills (LFT)	**130,968**	174,299
Total	**203,678**	372,007

7. Trade accounts receivable

7.1 Breakdown of trade accounts receivable

Trade accounts receivable comprise receivables for the sales of goods:

	Individual		Consolidated	
	06/30/2026	12/31/2025	**06/30/2026**	12/31/2025
Trade accounts receivable	**554,648**	572,397	**562,619**	579,117
Allowance for expected credit losses and finance charges	**(6,682)**	(4,935)	**(6,682)**	(4,935)
Total	**547,966**	567,462	**555,937**	574,182

(In thousands of reais)

7.2 Aging list of trade receivables

	06/30/2026	12/31/2025
Current		
Up to 30 days	**326,048**	335,792
31 to 60 days	**127,568**	130,580
61 to 90 days	**53,524**	61,377
91 to 120 days	**22,497**	20,439
121 to 150 days	**8,566**	11,925
151 to 180 days	**3,301**	1,420
Over 180 days	**755**	757
	542,259	562,290
Past due		
Up to 30 days	**5,136**	2,507
31 to 90 days	**3,588**	1,642
Over 90 days	**3,665**	5,958
	12,389	10,107
Allowance for expected credit losses	**(6,682)**	(4,935)
Total - Individual	**547,966**	567,462
Trade receivables (Lifar) – Current	**7,126**	4,708
Trade receivables (Lifar) – Past due	**845**	2,012
Total - Consolidated	**555,937**	574,182

7.3 Estimated credit losses

The allowance for expected credit losses is established based on the methodology from CPC 48/IFRS 9. The expected loss is estimated based on the analysis of the portfolio's performance, taking into consideration the likelihood of default and loss that each delay range presents. Changes in provision for impairment of accounts receivable are as follows:

	Individual		Consolidated	
	06/30/2026	12/31/2025	06/30/2026	12/31/2025
Balance at the beginning of the period	**(4,935)**	(7,956)	**(4,935)**	(7,956)
Additional allowance	**(2,200)**	(2,127)	**(2,200)**	(2,127)
Allowance amounts written off	**453**	5,148	**453**	5,148
Total	**(6,682)**	(4,935)	**(6,682)**	(4,935)

Recognition and derecognition of the allowance for expected credit losses were recorded in the statement of profit or loss for the year as "Net losses on receivables". The amounts charged to the allowance account are usually written off when there is no expectation of recovery of funds. The maximum exposure to credit risk at the reporting date is the carrying amount of each class of the abovementioned receivables.

(In thousands of reais)

8. Inventories

8.1 Breakdown of inventories

	Individual		Consolidated	
	06/30/2026	12/31/2025	**06/30/2026**	12/31/2025
Goods for resale	**1,163,513**	1,129,241	**1,164,312**	1,130,513
Finished products	**-**	-	**9,967**	7,957
Raw materials	**-**	-	**6,147**	5,580
Consumables/storeroom supplies	**13,461**	13,551	**24,312**	22,740
(-) Provision for inventory losses	**(153)**	(176)	**(258)**	(236)
Total	**1,176,821**	1,142,616	**1,204,480**	1,166,554

8.2 Estimated inventory losses

	Individual		Consolidated	
	06/30/2026	12/31/2025	**06/30/2026**	12/31/2025
Opening balance	**(176)**	(7)	**(236)**	(7)
Additional provision	**(3)**	(1,988)	**(148)**	(2,278)
Provision amounts written off	**26**	1,819	**126**	2,049
Closing balance	**(153)**	(176)	**(258)**	(236)

9. Income and social contribution taxes recoverable

	Individual		Consolidated	
	06/30/2026	12/31/2025	**06/30/2026**	12/31/2025
Corporate Income Tax (IRPJ)	**4,852**	3,560	**6,262**	4,983
Social Contribution Tax on Net Profit (CSLL)	**32**	-	**172**	141
Total	**4,884**	3,560	**6,434**	5,124

(In thousands of reais)

10. Taxes recoverable

10.1 Breakdown of taxes recoverable

	Individual		Consolidated	
	06/30/2026	12/31/2025	**06/30/2026**	12/31/2025
Current				
State Value-Added Tax (ICMS)	**20,902**	21,914	**21,962**	22,047
Contribution Tax on Gross Revenue for Social Integration Program (PIS)	**735**	123	**737**	123
Contribution Tax on Gross Revenue for Social Security Financing (COFINS)	**3,387**	544	**3,393**	544
Federal VAT (IPI)	**-**	-	**748**	-
Other	**175**	240	**175**	240
Total	**25,199**	22,821	**27,015**	22,954
Noncurrent				
State Value-Added Tax (ICMS)	**14,562**	14,465	**14,562**	14,465
Total	**14,562**	14,465	**14,562**	14,465

10.2 ICMS-ST in the state of Santa Catarina

On May 31, 2023, a final and unappealable decision was awarded by the State of Santa Catarina Court of Justice, which allows the recovery of ICMS-ST (tax substitution regime) amounts paid in excess of the amounts effectively adopted in sales, due to the ICMS-ST calculation methodology in the state of Santa Catarina. Until the second quarter of 2026, the Company partially calculated and accounted for credits (from 2011 to 2017) amounting to R$15,161, of which R$10,819 refers to principal and R$4,342 to restatement. This process is still awaiting final approval, and should there be additional credits, they will be accounted for after the process is completed.

On January 14, 2026, SEFAZ SC issued a partial order through TTD-597 Nº251900005710715, in the amount of R$9,642 referring to principal. The offsets commenced with the accessory tax filling for March 2026 and have continued throughout 2026, totaling 3,299 in offsets (R$3,214 of principal and R$85 referring to restatement).

10.3 Exclusion of ICMS-ST from the PIS and COFINS tax bases

On September 13, 2024, the decision that allows the recovery of PIS and COFINS amounts related to the exclusion of ICMS-ST from the PIS and COFINS tax bases owed by substituted taxpayers became final and unappealable at the Superior Court of Justice (TRF-4), granting rights to credits from September 2018 to September 2024.

Until the second quarter of 2026, an amount of R$33,162 had been recognized, consisting of R$24,563 in principal and R$8,599 in monetary restatement. Offsets began in February 2025 and the total amount was fully offset throughout 2025 and 2026.

(In thousands of reais)

grupo panvel

11. Investments in subsidiaries

11.1 Changes in investments

The Company's investments are accounted for in the Parent Company by the equity method, and are shown below:

	06/30/2026								
	Share Capital	**Shares held (unit)**	**(%) interest**	**Equity**	**Net income for the period**	**Opening balance at January 1**	**Equity pickup**	**Dividends/ capital increase**	**Total investments**
Dimesul Gestão Imobiliária Ltda.	**8,978**	**19,999**	**99.99%**	**36,134**	**4,434**	**31,699**	**4,434**	**-**	**36,134**
Laboratório Industrial Farmacêutico Lifar Ltda.	**12,478**	**1,247,837,668**	**99.99%**	**44,114**	**734**	**41,143**	**945**	**-**	**42,088**
Total						**72,842**	**5,379**	**-**	**78,222**

	12/31/2025								
	Share Capital	Shares held (unit)	(%) interest	Equity	Net income (loss) for the year	Opening balance at January 1	Equity pickup	Dividends/ capital increase	Total investments
Dimesul Gestão Imobiliária Ltda.	8,978	19,999	99.99%	31,700	4,294	52,903	4,294	(25,499)	31,699
Laboratório Industrial Farmacêutico Lifar Ltda.	12,478	1,247,837,668	99.99%	43,379	(60)	29,239	(78)	11,978	41,143
Total						82,142	4,216	(13,521)	72,842

(In thousands of reais)

11.2 Breakdown of investments

Information related to the subsidiaries is shown below:

	06/30/2026			
Subsidiaries in 2026	**Control**	**Total assets**	**Total liabilities**	**Equity**
Dimesul Gestão Imobiliária Ltda.	Direct interest	**36,752**	**618**	**36,134**
Laboratório Industrial Farmacêutico Lifar Ltda.	Direct interest	**76,479**	**32,365**	**44,114**
Lifar Distribuidora de Produtos Farmacêuticos Ltda.	Indirect interest	**15,750**	**6,756**	**8,994**

	12/31/2025			
Subsidiaries in 2025	**Control**	**Total assets**	Total liabilities	Equity
Dimesul Gestão Imobiliária Ltda.	Direct interest	32,355	656	31,700
Laboratório Industrial Farmacêutico Lifar Ltda.	Direct interest	77,416	34,037	43,379
Lifar Distribuidora de Produtos Farmacêuticos Ltda.	Indirect interest	12,232	4,177	8,055

(In thousands of reais)

12. Property, plant and equipment (PPE)

12.1 Summary of the movement in PPE (Individual)

	Properties	Machinery and equipment	Furniture and fixtures	Facilities	Computers and peripherals	Vehicles and aircraft	Improvements	PPE in progress	Total
Balance as at December 31, 2025									
Cost	98,992	89,353	87,387	190,660	101,466	21,258	334,908	22,775	946,799
Accumulated depreciation	(14,029)	(33,592)	(33,621)	(93,238)	(67,288)	(2,867)	(99,123)	-	(343,758)
Net balance as at December 31, 2025	84,963	55,761	53,766	97,422	34,178	18,391	235,785	22,775	603,041
As at June 30, 2026									
Acquisitions	**89**	**3,422**	**6,387**	**1,423**	**6,315**	**-**	**313**	**27,896**	**45,845**
Write-offs	**-**	**(71)**	**(98)**	**(451)**	**(105)**	**-**	**(930)**	**-**	**(1,655)**
Depreciation	**(764)**	**(2,809)**	**(3,745)**	**(8,069)**	**(6,170)**	**(371)**	**(11,872)**	**-**	**(33,800)**
Transfers	**(313)**	**(15)**	**(12)**	**10**	**118**	**-**	**13,776**	**(13,564)**	**-**
Net balance	**83,975**	**56,288**	**56,298**	**90,335**	**34,336**	**18,020**	**237,072**	**37,107**	**613,431**
As at June 30, 2026									
Cost	**98,764**	**92,623**	**93,363**	**190,283**	**106,399**	**21,258**	**347,054**	**37,107**	**986,851**
Accumulated depreciation	**(14,789)**	**(36,335)**	**(37,065)**	**(99,948)**	**(72,063)**	**(3,238)**	**(109,982)**	**-**	**(373,420)**
Net book balance	**83,975**	**56,288**	**56,298**	**90,335**	**34,336**	**18,020**	**237,072**	**37,107**	**613,431**

(In thousands of reais)

grupo panvel

12.2 Summary of the changes in PPE (Consolidated)

	Properties	Machinery and equipment	Furniture and fixtures	Facilities	Computers and peripherals	Vehicles and aircraft	Improvements	PPE in progress	Total
Balance as at December 31, 2025									
Cost	101,795	96,749	87,870	196,312	101,816	21,258	341,353	22,775	969,928
Accumulated depreciation	(15,437)	(36,065)	(33,830)	(96,274)	(67,464)	(2,867)	(101,423)	-	(353,360)
Net balance as at December 31, 2025	86,358	60,684	54,040	100,038	34,352	18,391	239,930	22,775	616,568
As at June 30, 2026									
Acquisitions	**179**	**3,555**	**6,413**	**1,703**	**6,323**	**-**	**337**	**27,896**	**46,406**
Write-offs	**(76)**	**(71)**	**(98)**	**(451)**	**(109)**	**-**	**(930)**	**-**	**(1,735)**
Depreciation	**(771)**	**(3,036)**	**(3,763)**	**(8,268)**	**(6,203)**	**(371)**	**(12,056)**	**-**	**(34,468)**
Transfers	**(313)**	**(15)**	**(12)**	**10**	**118**	**-**	**13,776**	**(13,564)**	**-**
Net balance	**85,377**	**61,117**	**56,580**	**93,032**	**34,481**	**18,020**	**241,057**	**37,107**	**626,771**
As at June 30, 2026									
Cost	**101,454**	**100,152**	**93,872**	**196,217**	**106,752**	**21,258**	**353,523**	**37,107**	**1,010,335**
Accumulated depreciation	**(16,077)**	**(39,035)**	**(37,292)**	**(103,185)**	**(72,271)**	**(3,238)**	**(112,466)**	**-**	**(383,564)**
Net book balance	**85,377**	**61,117**	**56,580**	**93,032**	**34,481**	**18,020**	**241,057**	**37,107**	**626,771**

(In thousands of reais)

12.3 Other information

The Company detected no indication that assets could be recorded at an amount above their recoverable amount.

The weighted average depreciation rates of property, plant and equipment, considering the useful lives of the assets, are as follows:

	Average depreciation rate (% p.a.)	
	2026	2025
Properties	**2**	2
Machinery and equipment	**7**	7
Furniture and fixtures	**9**	9
Facilities	**9**	9
Computers and peripherals	**24**	24
Vehicles	**20**	20
Aircraft	**4**	4
Improvements	**7**	7

13. Intangible assets

13.1 Summary of changes in intangible assets (Individual)

	Individual			
	Commerce Fund	**Software**	**Trademarks and formulas**	**Total**
Balance as at December 31, 2025				
Cost	26,150	213,034	361	239,545
Accumulated amortization	(21,081)	(111,290)	(13)	(132,384)
Net balance as at December 31, 2025	5,069	101,744	348	107,161
As at June 30, 2026				
Acquisitions	**60**	**14,815**	**-**	**14,875**
Amortization	**(622)**	**(14,564)**	**-**	**(15,186)**
Net balance	**4,507**	**101,995**	**348**	**106,850**
As at June 30, 2026				
Cost	**26,110**	**227,848**	**361**	**254,319**
Accumulated amortization	**(21,603)**	**(125,853)**	**(13)**	**(147,469)**
Net book balance	**4,507**	**101,995**	**348**	**106,850**

(In thousands of reais)

13.2 Summary of changes in intangible assets (Consolidated)

	Consolidated			
	Commerce Fund	Software	Trademarks and formulas	Total
Balance as at December 31, 2025				
Cost	26,150	214,348	1,408	241,906
Accumulated amortization	(21,081)	(112,070)	(229)	(133,380)
Net balance as at December 31, 2025	5,069	102,278	1,179	108,526
As at June 30, 2026				
Acquisitions	**60**	**14,906**	**161**	**15,127**
Write-offs	**-**	**-**	**(38)**	**(38)**
Amortization	**(622)**	**(14,639)**	**(43)**	**(15,304)**
Net balance	**4,507**	**102,545**	**1,259**	**108,311**
As at June 30, 2026				
Cost	**26,110**	**229,254**	**1,519**	**256,883**
Accumulated amortization	**(21,603)**	**(126,709)**	**(260)**	**(148,572)**
Net book balance	**4,507**	**102,545**	**1,259**	**108,311**

13.3 Other information

The Company detected no indication that assets could be recorded at an amount above their recoverable amount. The weighted average amortization rates of intangible assets are as follows:

	Average amortization rate (% p.a.)	
	2026	2025
Commerce Fund	**13**	13
Software	**18**	18
Trademarks and formulas	**10**	10

14. Deferred income tax and social contribution, net

14.1 Breakdown

Deferred income tax and social contribution are calculated on the corresponding temporary differences between the tax bases of assets and liabilities and their carrying amounts recorded in the interim financial statements. The applicable tax rates, currently defined for calculation of deferred taxes, are 25% for income tax and 9% for social contribution tax. Deferred tax assets are recognized to the extent that it is probable that future taxable profit will be available to offset temporary differences, based on deferred income projections prepared and grounded on internal assumptions and future economic scenarios that may, therefore, suffer changes.

(In thousands of reais)

	Individual		Consolidated	
	06/30/2026	12/31/2025	**06/30/2026**	12/31/2025
Temporary additions				
(Reversal) Provision for inventory losses	**153**	176	**258**	236
(Reversal) Provision for labor and tax indemnities	**7,502**	6,811	**8,514**	7,799
(Reversal) Provision for profit sharing	**-**	18,190	**-**	18,191
(Reversal) Allowance for expected credit losses	**6,682**	4,935	**6,682**	4,935
Net effect - IFRS 16	**82,666**	75,493	**82,666**	75,493
Fair value - Matching shares	**4,096**	8,427	**4,096**	8,427
Foreign exchange differences – Cash basis	**(8)**	3,860	**(8)**	3,860
Derivative instruments	**-**	5,354	**-**	5,354
Other provisions	**12,379**	9,840	**12,524**	9,903
Total tax base	**113,470**	133,086	**114,732**	134,198
Income tax at the rate of 25%	**28,839**	33,272	**29,154**	33,549
Income tax on tax loss	**1,992**	2,621	**9,025**	9,472
Social contribution tax at the rate of 9%	**10,382**	11,978	**10,496**	12,078
Social contribution tax on tax loss	**2,312**	2,383	**4,843**	4,850
Total deferred tax assets	**43,525**	50,254	**53,518**	59,949
Total deferred taxes, net	**43,525**	50,254	**53,518**	59,949

14.2 Deferred tax realization

Based on the Company's deferred income projections and considering the history of realization of the assets that generated the income and social contribution tax balance, the estimated realization schedule is as follows:

	Individual	Consolidated
	06/30/2026	**06/30/2026**
2026	**21,761**	**26,758**
2027	**5,441**	**6,690**
2028	**5,441**	**6,690**
2029	**5,441**	**6,690**
2030	**5,441**	**6,690**
Total	**43,525**	**53,518**

(In thousands of reais)

15. Reconciliation of income and social contribution taxes

	Individual		Consolidated	
	06/30/2026	06/30/2025	**06/30/2026**	06/30/2025
Income before income tax and social contribution	**71,484**	56,388	**72,535**	56,878
Combined tax rate	**34%**	34%	**34%**	34%
Tax expense at nominal rate	**(24,305)**	(19,172)	**(24,662)**	(19,339)
Other nondeductible revenue (expenses)	**(767)**	(478)	**(695)**	24
Management profit sharing	**(1,557)**	-	**(1,557)**	-
Interest on equity – Benefit	**10,540**	9,010	**10,540**	9,010
Equity pickup	**1,829**	903	**-**	-
Credits arising from lawsuits	**543**	2,331	**543**	2,331
Tax incentives – Workers' Meal Program (PAT)	**46**	60	**46**	60
Tax incentives – investment grant – deemed income	**3,513**	-	**3,513**	-
Reversal of the effect of the taxable profit on the subsidiary using the deemed income regime	**-**	-	**1,808**	1,132
Taxation under deemed income using gross revenue for the tax base	**-**	-	**(894)**	(1,078)
Tax incentives – Technological innovation – Benefit	**1,509**	1,502	**1,563**	1,502
Tax incentives – Empresa Cidadã	**597**	-	**597**	-
Reversal of tax adjustment effects from prior periods	**158**	-	**229**	-
Effect of the portion exempt from the 10% surtax of income tax – benefit	**12**	12	**36**	36
	(7,882)	(5,832)	**(8,933)**	(6,322)
Income and social contribution taxes in profit or loss				
Current income tax and social contribution	**(1,153)**	(3,302)	**(2,501)**	(5,042)
Deferred income tax and social contribution	**(6,729)**	(2,530)	**(6,432)**	(1,280)
Total income and social contribution taxes	**(7,882)**	(5,832)	**(8,933)**	(6,322)
Effective rate	**11%**	10.3%	**12.4%**	11.1%

16. Trade accounts payable

	Individual		Consolidated	
	06/30/2026	12/31/2025	**06/30/2026**	12/31/2025
Trade accounts payable - domestic	**641,576**	725,790	**642,328**	725,307
Trade accounts payable – related parties	**12,311**	8,971	**-**	-
Trade accounts payable – forfaiting	**1,957**	-	**1,957**	
Total	**655,844**	734,761	**644,285**	725,307

In the first half of 2026, the Company entered into agreements with financial institutions to allow its suppliers, at their sole discretion, to collect receivables in advance from the supply of goods and services. When the supplier opts for the advanced receivables, the credit right is transferred to the financial institution, and the Company makes the payment in the same amount and on the date originally agreed upon with the supplier.

(In thousands of reais)

The agreements do not change the originally agreed-upon terms or amounts and do not provide for premiums, rebates, or other financial benefits in favor of the Company. The rates and charges arising from the advanced receivables are defrayed entirely by the suppliers, without any additional costs to the Company.

Considering the contractual conditions and the economic substance of the transactions, Management concluded that these obligations maintain a nature and function similar to other trade accounts payable and remain related to the Company's operating cycle. Consequently, the balances are recognized under "Trade accounts payable – forfaiting", and the corresponding payments are presented as cash flows from operating activities.

As at June 30, 2026, obligations related to forfaiting agreements total R$ 1,957 in the Individual and in the Consolidated (R$ 0 as at December 31, 2025) and correspond to trade notes already paid to suppliers by financial institutions. The agreements have similar terms and a maturity date of up to 120 days, starting from the invoice date.

17. Loans and financing

17.1 Breakdown of loans and financing

		Individual		Consolidated	
	Rate range (p.a.)	**06/30/2026**	12/31/2025	**06/30/2026**	12/31/2025
Domestic currency					
Debentures – CRI	CDI + 1.30%	**262,791**	263,339	**262,791**	263,339
Debenture – 6th issue	CDI + 0.55%	**168,002**	167,753	**168,002**	167,753
FINEP	TR + 3.30%	**96,981**	96,719	**96,981**	96,719
BNDES - Working capital	7.42%	**61,730**	59,539	**81,196**	81,791
BNDES Recon	3.80%	**-**	-	**5,384**	5,384
Foreign currency					
Operation 4131 Itaú (*)	CDI + 0.80%	**-**	96,988	**-**	96,988
Total		**589,504**	684,338	**614,354**	711,974
Current		**140,250**	185,960	**146,282**	191,815
Noncurrent		**449,254**	498,378	**468,072**	520,159

(*) Operation issued in Euro, translated at the average rate (Euro) of December 31, 2025 (R$6.4692) for which the Company contracted derivative financial instruments (swap) for CDI + 0.80%.

The Executive Board monitors the forecasts for the Company's liquidity requirements to ensure it has sufficient cash to meet its operating needs. The global limits of credit facilities granted to the Company are in amounts sufficient to not generate the risk of exceeding such limits or of breaching loan agreement clauses or covenants. This forecast takes into consideration the Company's debt financing plans. For the increase in indebtedness, the Company considered its growth strategy and the current economic scenario of the segment. This indebtedness is monitored through the analysis of available funds and the calculation of the net debt.

(In thousands of reais)

17.2 Payment flow of loans and financing

	Individual		Consolidated	
Year of payment	**06/30/2026**	12/31/2025	**06/30/2026**	12/31/2025
2026	**90,250**	185,960	**93,319**	191,815
2027	**112,972**	112,971	**119,063**	119,062
2028	**177,143**	176,471	**183,290**	182,618
2029	**79,408**	79,376	**85,556**	85,524
2030 to 2036	**129,731**	129,560	**133,126**	132,955
Total	**589,504**	684,338	**614,354**	711,974

17.3 Debt Service Coverage Ratio ("DSCR") greater than or equal to 1.2 times

In which: "'DSCR" means the ratio of Adjusted EBITDA (as defined below) to Debt Service; and "Debt Service" means the finance costs related to the last 12 months, calculated on an accrual basis, on a consolidated basis by the Issuer, namely: (a) interest related to bank debt (net of income from short-term investments), (b) the cash-impact portion of inflation adjustments and foreign exchange fluctuations on interest related to debt instruments, (c) interest paid on the Debentures and other securities issued in the domestic and international financial and capital markets (net of income from investments in securities and public or private securities of any nature), (d) cash-impact finance costs related to intragroup loans recorded in liabilities (net of cash-impact finance income received in connection with intragroup loans recorded in assets), as well as (e) the amount effectively disbursed in connection with liabilities arising from debt hedging derivatives (net of amounts effectively received in connection with assets arising from debt hedging derivatives).

17.4 Adjusted Net Debt/Adjusted EBITDA ratio, calculated in accordance with the methodology set forth below, not exceeding 2.5 times

In which: for purposes of calculating Adjusted EBITDA, the accumulated performance over the 12 months preceding the closing date of the financial statements shall be considered, which will be determined based on the consolidated balance sheets for March, June, September, and December of each fiscal year. For the purposes of this item: "Adjusted Net Debt" means the sum of the amounts corresponding to: (i) short-term bank loans; (ii) short-term debentures; (iii) long-term bank loans; (iv) long-term debentures; (v) long-term loans; (vi) short-term bank leasing operations; (vii) long-term bank leasing operations; (viii) accounts payable or receivable related to derivative transactions, if any, less cash and cash equivalents, short-term investments, and marketable securities; and also (ix) all intragroup loans, whether assets or liabilities, entered into among group companies, associates or not; "Adjusted EBITDA", as provided for in CVM Instruction 527, dated October 4, 2012, as amended; and "Net Debt / Adjusted EBITDA" means the Adjusted Net Debt-to-Adjusted EBITDA ratio.

The Company is compliant with all covenants as at June 30, 2026.

(In thousands of reais)

The loan agreements currently in force also contain non-financial covenants on accelerated maturity, the most relevant of which are described below:

- Defaulting on debts and/or other contracts with financial institutions that are lenders;
- Enforcement of judicial or extrajudicial measures that may affect the Company's ability to pay;
- Transfer of debts to third parties without the consent of lenders;
- Changes to the Company's corporate purpose or changes in shareholding control without the financial institution formally expressing its consent and maintaining the agreements.

17.5 Cash flows from financing activities

17.5.a Cash flows from financing activities - Individual

	Individual			
	Finance leases	**Loans, financing and debentures**	**Interest on equity payable**	**Total**
Balance as at December 31, 2025	794,291	684,338	58,018	1,536,647
Changes in cash	**(106,737)**	**(126,335)**	**(28,799)**	**(261,871)**
Payment of financing activities - principal	**-**	**(90,000)**	**-**	**(90,000)**
Transaction costs	**-**	**1,010**		**1,010**
Payment of IOE	**-**	**-**	**(28,799)**	**(28,799)**
Leases paid	**(66,797)**	**-**	**-**	**(66,797)**
Interest paid in the year	**(39,940)**	**(37,345)**	**-**	**(77,285)**
Noncash changes	**101,842**	**31,501**	**26,861**	**160,204**
Remeasurement of contracts and new contracts - IFRS 16	**68,394**	**-**	**-**	**68,394**
Write-offs of contracts - IFRS 16	**(6,492)**	**-**	**-**	**(6,492)**
IOE recognized in the period	**-**	**-**	**26,861**	**26,861**
Interest recognized in the year	**39,940**	**31,501**	**-**	**71,441**
Balance as at June 30, 2026	**789,396**	**589,504**	**56,080**	**1,434,980**

(In thousands of reais)

17.5.b Cash flows from financing activities - Consolidated

	Consolidated			
	Finance leases	Loans, financing and debentures	Interest on equity payable	Total
Balance as at December 31, 2025	794,291	711,974	58,018	1,564,283
Changes in cash	**(106,737)**	**(129,971)**	**(28,799)**	**(265,507)**
Payment of financing activities - principal	-	(92,740)	-	(92,740)
Transaction costs	-	1,010	-	1,010
Payment of IOE	-	-	(28,799)	(28,799)
Leases paid	(66,797)	-	-	(66,797)
Interest paid in the period	(39,940)	(38,241)	-	(78,181)
Noncash changes	**101,842**	**32,351**	**26,861**	**161,054**
Remeasurement of contracts and new contracts - IFRS 16	68,394	-	-	68,394
Write-offs of contracts - IFRS 16	(6,492)	-	-	(6,492)
IOE recognized in the period	-	-	26,861	26,861
Interest recognized in the period	39,940	32,351	-	72,291
Balance as at June 30, 2026	**789,396**	**614,354**	**56,080**	**1,459,830**

The balances of loans and financing as at June 30, 2026 and December 31, 2025 are presented at amortized cost. The aging list of loans and financing is presented in Note 4.1.3 Liquidity risk and Note 17.2 Payment flow of loans and financing.

18. Tax obligations

	Individual		Consolidated	
	06/30/2026	12/31/2025	**06/30/2026**	12/31/2025
IRPJ	**599**	4,170	**1,146**	4,848
CSLL	**137**	1,789	**338**	2,037
PIS	**168**	641	**211**	705
COFINS	**767**	2,966	**970**	3,269
IRRF	**4,912**	8,320	**4,950**	8,454
ICMS	**70,346**	35,554	**73,459**	37,803
Other payables	**2,233**	2,122	**2,524**	2,521
Total	**79,162**	55,562	**83,598**	59,637

19. Profit sharing payable

	Individual		Consolidated	
	06/30/2026	12/31/2025	**06/30/2026**	12/31/2025
Employee profit sharing	-	18,190	-	18,401
Total	-	18,190	-	18,401

(In thousands of reais)

20. Leases

The Company recognizes its lease contracts in accordance with NBC TG 06 (R3) – Leases, applying the right-of-use asset and lease liability recognition model for contracts that meet the definition of lease. The contracts mainly cover property and vehicle leases.

At the commencement date of each contract, the Company recognizes:
• A right-of-use asset, representing the right to use the leased asset over the contractual term;
• A lease liability, corresponding to the obligation to make the agreed future payments.

These amounts are measured at the present value of future payments, discounted at the Company's incremental rate, which corresponds to the weighted average of borrowing rates.
The right-of-use asset is depreciated on a straight-line basis over the shorter of the lease term or the useful life of the asset, as provided for in the accounting standard.

20.1 Breakdown of right-of-use assets

Technical pronouncement CPC 06 (R2)/IFRS 16 requires that all lease contracts (except those that fall under the exceptions) be recognized as liabilities, with a corresponding entry in right-of-use assets. The breakdown of the right of use for property and vehicle lease contracts, as well as their defined useful lives, is described in the table below:

	Individual and Consolidated	
	Useful life (years)	**06/30/2026**
Properties	2 to 17	**703,978**
Vehicles	2 to 4	**2,752**
Total		**706,730**

20.2 Movement in right-of-use assets

The movement in right-of-use assets in Individual and in Consolidated is as follows:

	Individual and Consolidated		
	Properties	**Vehicles**	**Total**
Balance as at December 31, 2025	715,063	3,734	718,797
New contracts and remeasurement	**68,193**	**201**	**68,394**
Terminations	**(5,780)**	**-**	**(5,780)**
Amortization	**(73,497)**	**(1,184)**	**(74,681)**
Balance as at June 30, 2026	**703,979**	**2,751**	**706,730**

(In thousands of reais)

20.3 Movement in lease liabilities

The Company has obligations arising from real estate and vehicle lease agreements, accounted for under the criteria of IFRS 16. Changes in the Company's lease liability balance until June 30, 2026 were as follows:

	Individual and Consolidated		
	Properties	Vehicles	Total
Balance as at December 31, 2025	790,309	3,982	794,291
New contracts and remeasurement	**68,193**	**201**	**68,394**
Write-offs	**(6,492)**	**-**	**(6,492)**
Interest	**39,717**	**223**	**39,940**
Payment of leases	**(105,314)**	**(1,423)**	**(106,737)**
Balance as at June 30, 2026	**786,413**	**2,983**	**789,396**
Current	**137,956**	**1,949**	**139,905**
Noncurrent	**648,457**	**1,034**	**649,491**

20.4 Amount recognized in profit or loss

	Individual and Consolidated			
	Quarter		Accumulated	
	06/30/2026	06/30/2025	**06/30/2026**	06/30/2025
Recognition in profit or loss				
Amortization of right of use	**37,381**	35,231	**74,681**	69,760
Interest on lease liabilities	**20,054**	17,324	**39,940**	34,162

20.5 Complementary information

A simplified retrospective approach was applied, and, at the moment of the transaction, lease liabilities are measured by the current value of remaining payments, discounted at the incremental financing rate. Initially, the assets' right of use was measured at the equivalent amount of lease liabilities, and the practical expedient used allows the lessee to exclude initial direct costs from the measurement of the right-of-use asset at the date of initial application.

In order to fulfill CVM Circular Letter No. 02/2019 and technical pronouncement CPC 06 (R2)/IFRS 16, justified by the fact that the Company did not apply the nominal flows methodology due to the restriction imposed by IFRS 16 for future inflation predictions, the companies shall present the minimum inputs for users of the financial statements that are able to reach that information. Thus, the Company has chosen to disclose these minimum inputs so that users can reach the information. The inputs are as such:

- Average nominal discount rate applied – between 5% and 16% p.a.
- Incremental rate applied corresponds to the weighted average of the Company's loan funding rates, currently at 13.49% p.a.

Also, the Company presents below the maturity analysis of lease liabilities, with the disclosure of non-discounted future payment flows as at June 30, 2026.

(In thousands of reais)

In addition, for information purposes, we segregate below the principal and interest amounts. This additional information is not required by NBC TG 06 (R3) and is only given in order to improve transparency and reconciliation.

	Individual and Consolidated		
As at June 30, 2026	**Effective principal flow**	**Estimated interest (i)**	**Inflated flow**
<1 year	**216,652**	**46,100**	**170,553**
1 to 2 years	**373,528**	**88,065**	**285,464**
3 to 4 years	**253,353**	**70,841**	**182,512**
>5 years	**231,153**	**80,286**	**150,867**
Total	**1,074,686**	**285,292**	**789,396**

(i) The present value of leases payable was calculated considering the projection for future fixed payments, discounted by the rate of 13.49% p.a. (12.88% p.a. - Dec/25), which was created from the basic interest funding rate.

The Company maintains lease contracts with natural-person and legal-entity lessors, however, the right to use PIS/COFINS credits only comprises contracts whose lessor is a legal entity and, considering this condition, eligible contracts amount to R$863,250 in contractual flow, with a PIS/COFINS projection of R$79,850.

21. Provisions for contingencies

The Company is a party to civil, labor and tax claims, in administrative and legal proceedings. Where applicable, claims are supported by judicial deposits. Provisions for any losses arising from these proceedings are estimated and restated by the Executive Board, supported by the opinion of its external and internal legal advisors.

21.1 Breakdown of provisions for contingencies

Provisions are recognized for proceedings assessed as probable losses, as follows:

	Individual		Consolidated	
	06/30/2026	12/31/2025	**06/30/2026**	12/31/2025
Labor	**7,502**	6,635	**7,595**	6,739
Tax	**-**	-	**918**	884
Noncurrent	**7,502**	6,635	**8,513**	7,623
Judicial deposits	**3,307**	4,205	**3,307**	4,205

(In thousands of reais)

21.2 Changes in provisions for contingencies

Changes in provisions for labor and tax claims are shown in the table below:

	Individual		Consolidated	
	06/30/2026	12/31/2025	**06/30/2026**	12/31/2025
Labor and tax				
Balance at the beginning of the year	**6,635**	6,348	**7,623**	7,368
New provisions	**2,952**	5,580	**3,009**	5,912
Write-offs due to payment	**(2,085)**	(4,355)	**(2,085)**	(4,355)
Reversal	**-**	(938)	**(34)**	(1,302)
Balance at the end of the year	**7,502**	6,635	**8,513**	7,623

21.3 Lawsuits assessed as possible loss

The lawsuits assessed as possible losses based on the Company's legal counsel's opinion as at June 30, 2026 and December 31, 2025 are described below.

	06/30/2026			
	Individual		**Consolidated**	
	Number	**Amount**	**Number**	**Amount**
Civil	**7**	**481**	**7**	**481**
Labor*	**752**	**33,482**	**766**	**34,031**
Total	**759**	**33,963**	**773**	**34,512**

	12/31/2025			
	Individual		Consolidated	
	Number	Amount	Number	Amount
Civil	6	680	6	680
Labor*	693	29,679	709	30,030
Total	699	30,359	715	30,710

*Most recurring labor claims originate from complaints on overtime and payroll disparity.

22. Net Equity

22.1 Share Capital

At the Special General Meeting held on April 30, 2026, a capital increase from R$1,227,143 to R$1,294,032 was approved (R$1,279,584 net of share issue costs), through full capitalization of the Reserve for Future Capital Increase, without issue of new shares. The Company's capital comprises 150,377,481 registered, book-entry, common shares with no par value.

22.2 Treasury shares

At June 30, 2026, the Company had 1,001,855 treasury shares (1,692,866 at December 31, 2025), whose average cost value was R$10,292 (R$21,359 at December 31, 2025). The share market price as at June 30, 2026 was R$10.99 (R$11.99 at December 30, 2025).

(In thousands of reais)

Shares already exercised are also removed from treasury shares, i.e., transferred to beneficiaries, as of the expiration of the vesting of the Matching Shares programs.

In the first quarter of 2026, the Company anticipated the transfer of shares related to the vesting of the Executive Board's Matching Shares Program, originally scheduled for the coming months. The transaction involved 453,448 shares, with no material financial impact in the quarter since expenses had already been recognized proportionally throughout the acquisition period. The anticipation is in line with the retention strategy and reinforces the Company's commitment to corporate governance and long-term leadership alignment.

In the second quarter of 2026, the treasury shares account was impacted by the grant of shares under the 7th program at R$5,463 (R$3,697 in the second quarter of 2025, relating to the 6th program), and by the transfer of shares exercised during the period, relating to the vesting of the Matching Shares Program, involving a total of 45,497 shares, with no financial impact. Changes in treasury shares are as follows:

	Individual	
	Common shares	R$
Balance as at 12/31/2025	(1,692,866)	(21,359)
Acquisition of shares	**(161,300)**	**(2,137)**
Shares granted under the 7th program	**353,366**	**5,463**
Disposal/transfer of shares – in advance	**453,448**	**7,038**
Disposal/transfer of shares – exercise of vesting	**45,497**	**703**
Balance as at 06/30/2026	**(1,001,855)**	**(10,292)**

	Share price		
	Minimum	Maximum	Average cost
From 01/01/2025 to 12/31/2025	7.89	11.99	9.20
From 01/01/2026 to 06/30/2026	**10.51**	**16.34**	**11.36**

22.3 Income reserves

22.3.1 Reserve for future capital increase

As at December 31, 2025, as approved at the Board of Directors' meeting, the Company incorporated the balance of the tax incentive reserve into the income reserve, with the subsequent capitalization of R$180,684, further reinforcing its capital structure.

Also in December 2025, a reserve for future capital increase of R$ 66,889 was set up, which was contributed to share capital at an Special General Meeting held, on second call, on May 22, 2026, in accordance with the management proposal disclosed to the market on March 31, 2026.

(In thousands of reais)

22.3.2 Legal reserve

The legal reserve is set up at 5% of net income for each year, under the terms of Law No. 6404/76, article 193, capped at 20% of capital.

22.3.3 Dividends and interest on equity additional to those proposed

The mandatory minimum dividends of 25% are recognized pursuant to the statutory provisions. The additional amount, when approved by the Board of Directors in the performance of its statutory duties, is directly recognized in liabilities, considering the obligation assumed on the respective resolution date, with the subsequent Annual Shareholders' Meeting being intended for the ratification.

22.3.4 Compensation paid to shareholders

In accordance with the provisions of Dimed's Articles of Incorporation, the mandatory minimum dividend is 25% on net income for the year, considering the adjustments provided for in the corporation law. Management proposed the payment of compensation to shareholders through interest on equity, which is incorporated into mandatory minimum dividends, as permitted by the prevailing laws.
The resolved amount of interest on equity as well as the value per share are described below:

Date of resolution	Amount	Installments	Net unit value per share	Date of payment			
				1st installment	2nd installment	3rd installment	4th installment
06/23/2026	**18,000**	**4**	**0.09946413**	**03/31/2027**	**04/30/2027**	**05/31/2027**	**08/31/2027**
03/23/2026	**13,000**	**3**	**0.07414344**	**03/31/2027**	**04/30/2027**	**05/31/2027**	**-**
12/31/2025	22,000	3	0.12568861	03/31/2027	04/30/2027	05/31/2027	-
09/30/2025	3,000	1	0.01708333	05/31/2026	-	-	-
06/30/2025	13,500	2	0.07690366	05/31/2026	08/31/2026	-	

22.4 Capital reserves

This reserve is set up and matched against the expenses with the stock option plan granted by the Company to its managing officers and employees (Note 23). The difference between the strike price of Matching Share plans and the cost of acquisition by the beneficiaries is recognized in the Goodwill reserve.

23. Incentive plan in connection with shares - Individual

23.1 Conditions of the Matching Share plan

The shares granted as an incentive under Dimed's Matching Share Plan may not exceed the maximum limit of 3% of the shares of the Company's subscribed and paid-in capital. Beneficiaries will be granted the right to receive, free of charge, the maximum proportion of up to five (5) and minimum of one (1) Matching Share for each common share of the Company, acquired under the Plan ("Own shares"), up to

(In thousands of reais)

the limit established in their respective Private Share Granting Instruments and Adhesion to Dimed's Matching Share Plan, provided that certain conditions are met.
Matching shares will be subject to a progressive Vesting period of three years, during which the beneficiary must maintain his/her relationship with the Company. The Vesting period will start on the grant date and within this period the Matching shares will become Mature Matching Shares and will be liquidated to the beneficiaries on the dates specified below:

Anniversary	Mature Matching Shares
1st anniversary of the grant date	1/3 (one third) of the total Matching Shares
2nd anniversary of the grant date	1/3 (one third) of the total Matching Shares
3rd anniversary of the grant date	1/3 (one third) of the total Matching Shares

Upon execution of the grant agreement, the beneficiary must expressly authorize the blocking of the negotiation and encumbrance of the "Own shares" acquired, during the Vesting period, in the records of the depositary institution of the Company's book-entry shares.

23.2 Changes in the Matching Share plan

	Own shares	Matching shares
Balance as at December 31, 2024	640,939	1,199,412
Options granted	240,192	847,474
Options exercised	-	(578,590)
Dissenting holders	-	(4,876)
Balance as at December 31, 2025	881,131	1,463,420
Options granted	**353,366**	**1,242,022**
Options exercised (*)	**-**	**(695,719)**
Dissenting holders	**-**	**(12,166)**
Balances as at June 30, 2026	**1,234,497**	**1,997,557**

(*) The gross number of mature Matching shares was converted into 498,945 net shares in 2026.

23.3 Amounts recognized in the year

The recognition of share-based plans is calculated according to the fair value of the assets granted, the amount of assets granted, and the grace period. The Matching Shares are allocated in three equal lots, with vesting terms of one, two and three years, respectively, from the date of grant. For accounting purposes, the fair value of each lot was calculated based on the average share price on B3 on the date of the grant, discounted from the expected dividend yield, since the beneficiaries are not entitled to dividends during the grace period. In accordance with the accounting standard, the lockup period of Own Shares does not affect the fair value of the assets.

The accumulated amount recognized by the Company in 2026 as fair value of the Matching Shares programs until the current quarter was R$3,012 (R$2,534 in 2025). In the second quarter of 2026 the amount was R$ 991 (R$ 673 in the second quarter of 2025).

(In thousands of reais)

24. Earnings per share

24.1 Basic

Basic earnings per share are calculated by dividing the profit attributable to the Company's shareholders by the weighted average number of common shares issued during the year, excluding common shares purchased by the Company and held as treasury shares

24.2 Diluted

Diluted earnings per share are calculated by adjusting the weighted average number of outstanding common shares, to assume the conversion of all dilutive potential common shares.

	06/30/2026	12/31/2025
	Common shares (ON)	Common shares (ON)
Number of shares		
Total weighted average number of shares	**150,377,481**	150,377,481
Weighted number of treasury shares	**(1,401,516)**	(1,340,728)
Weighted average number of outstanding shares	**148,975,965**	149,036,753
% of shares in relation to the total number	**100%**	100%
Basic earnings per share		
Numerator: Net income attributable to each class of shares (R$)	**63,602,172**	124,605,259
Denominator: Weighted average number of outstanding shares	**148,975,965**	149,036,753
Basic earnings per share (R$)	**0.43**	0.84
Diluted earnings per share		
Numerator: Net income attributable to each class of shares (R$)	**63,602,172**	124,605,259
Denominator: Weighted average number of outstanding shares and matching shares	**150,011,842**	150,227,680
Diluted earnings per share (R$)	**0.42**	0.83

25. Revenue

The Company's revenue derives mainly from the resale of medicine and personal care and beauty products.
Reconciliation between gross revenues for tax purposes and the revenues stated in the statement of profit or loss for the year (individual and consolidated) is as follows:

	Quarter			
	Individual		**Consolidated**	
	06/30/2026	06/30/2025	**06/30/2026**	06/30/2025
Gross sales of products and services	**1,631,015**	1,408,961	**1,635,294**	1,413,727
Sales taxes	**(107,653)**	(83,083)	**(108,721)**	(84,146)
Returns and unconditional discounts	**(16,884)**	(15,426)	**(17,423)**	(15,835)

(In thousands of reais)

Net revenue	**1,506,478**	1,310,452	**1,509,150**	1,313,746

	Accumulated			
	Individual		Consolidated	
	06/30/2026	06/30/2025	**06/30/2026**	06/30/2025
Gross sales of products and services	**3,186,614**	2,760,815	**3,206,107**	2,770,423
Sales taxes	**(208,991)**	(165,041)	**(213,096)**	(166,774)
Returns and unconditional discounts	**(33,272)**	(29,578)	**(34,200)**	(31,215)
Net revenue	**2,944,351**	2,566,196	**2,958,811**	2,572,434

26. Cost of goods sold and services provided

	Quarter			
	Individual		Consolidated	
	06/30/2026	**06/30/2025**	**06/30/2026**	**06/30/2025**
Cost of products sold	**(1,102,179)**	(972,082)	**(1,100,274)**	(962,796)
Cost of real properties sold	**-**	-	**(762)**	(10,269)
Reimbursement of capital contribution costs	**94,509**	101,968	**94,509**	101,968
Revenue – campaign funds	**49**	317	**49**	317
Taxes on funds	**(8,747)**	(9,461)	**(8,747)**	(9,461)
Total	**(1,016,368)**	(879,258)	**(1,015,225)**	(880,241)

	Accumulated			
	Individual		Consolidated	
	06/30/2026	06/30/2025	**06/30/2026**	06/30/2025
Cost of products sold	**(2,174,326)**	(1,926,878)	**(2,172,047)**	(1,909,446)
Cost of real properties sold	**-**	-	**(5,335)**	(18,059)
Reimbursement of capital contribution costs	**192,967**	208,290	**192,967**	208,290
Revenue – campaign funds	**73**	714	**73**	714
Taxes on funds	**(17,856)**	(19,333)	**(17,856)**	(19,333)
Total	**(1,999,142)**	(1,737,207)	**(2,002,198)**	(1,737,834)

The amounts reimbursed by suppliers relating to lease of properties, promotional funds and advertising and publicity expenses are deducted from cost of sales, and the average period for reimbursement is 30 to 60 days. Such reimbursement is recognized when the contractual conditions are likely to be met.

(In thousands of reais)

27. Expenses by nature

27.1 Breakdown of selling expenses

	Quarter			
	Individual		Consolidated	
	06/30/2026	06/30/2025	**06/30/2026**	06/30/2025
Selling expenses				
Personnel expenses	**(190,660)**	(175,276)	**(191,208)**	(175,982)
Expenses with utilities and services	**(22,113)**	(22,411)	**(22,259)**	(22,357)
Lease expenses	**(16,919)**	(13,072)	**(16,937)**	(12,950)
Freight expenses	**(18,115)**	(16,140)	**(18,605)**	(16,519)
Credit card fee expenses	**(18,765)**	(15,762)	**(18,822)**	(15,814)
Advertising expenses	**(14,178)**	(9,075)	**(14,195)**	(9,095)
Depreciation and amortization expenses	**(58,163)**	(53,882)	**(58,175)**	(53,891)
Employee profit sharing	**(49)**	(38)	**(157)**	(47)
Software maintenance and licensing expenses	**(5,688)**	(4,008)	**(5,702)**	(4,017)
Use and consumption expenses	**(7,027)**	(6,624)	**(7,077)**	(6,686)
Insurance expenses	**(1,918)**	(1,479)	**(1,929)**	(1,495)
Inventory losses	**(7,726)**	(6,657)	**(8,273)**	(7,208)
Other selling expenses	**(13,532)**	(3,060)	**(13,656)**	(3,673)
Total	**(374,853)**	(327,484)	**(376,995)**	(329,734)

	Accumulated			
	Individual		Consolidated	
	06/30/2026	06/30/2025	**06/30/2026**	06/30/2025
Selling expenses				
Personnel expenses	**(373,130)**	(338,622)	**(374,156)**	(339,404)
Expenses with utilities and services	**(43,930)**	(53,753)	**(44,268)**	(54,171)
Lease expenses	**(33,029)**	(25,619)	**(33,035)**	(25,333)
Freight expenses	**(33,964)**	(32,024)	**(34,940)**	(32,898)
Credit card fee expenses	**(36,641)**	(30,556)	**(36,754)**	(30,673)
Advertising expenses	**(25,055)**	(17,787)	**(25,089)**	(17,834)
Depreciation and amortization expenses	**(115,947)**	(106,906)	**(115,973)**	(106,927)
Employee profit sharing	**(123)**	(87)	**(231)**	(96)
Software maintenance and licensing expenses	**(11,875)**	(7,895)	**(11,903)**	(7,913)
Use and consumption expenses	**(13,776)**	(13,378)	**(13,867)**	(13,453)
Insurance expenses	**(3,583)**	(3,157)	**(3,596)**	(3,187)
Inventory losses	**(13,083)**	(11,355)	**(13,839)**	(12,053)
Other selling expenses	**(18,999)**	(5,598)	**(19,667)**	(6,375)
Total	**(723,135)**	(646,737)	**(727,318)**	(650,317)

(In thousands of reais)

27.2 Breakdown of general and administrative expenses

	Quarter			
	Individual		Consolidated	
	06/30/2026	06/30/2025	**06/30/2026**	06/30/2025
General and administrative expenses				
Personnel expenses	**(18,014)**	(18,394)	**(18,599)**	(18,750)
Expenses with utilities and services	**(17,078)**	(10,759)	**(17,486)**	(11,400)
Lease expenses	**(179)**	(276)	**(190)**	(280)
Depreciation and amortization expenses	**(3,838)**	(3,771)	**(3,951)**	(3,868)
Employee profit sharing	**(595)**	(56)	**(628)**	(60)
Management profit sharing	**(7,147)**	(5,050)	**(7,147)**	(5,050)
Banking expenses	**(192)**	(528)	**(194)**	(535)
Management compensation	**(2,114)**	(1,939)	**(2,114)**	(1,940)
Software maintenance and licensing expenses	**(4,922)**	(3,456)	**(4,944)**	(3,504)
Consumption expenses	**(217)**	(224)	**(237)**	(266)
Insurance expenses	**(101)**	(113)	**(133)**	(140)
Other administrative expenses	**(1,388)**	(2,561)	**(1,425)**	(2,645)
Total	**(55,785)**	(47,127)	**(57,048)**	(48,438)

	Accumulated			
	Individual		Consolidated	
	06/30/2026	06/30/2025	**06/30/2026**	06/30/2025
General and administrative expenses				
Personnel expenses	**(35,940)**	(37,810)	**(37,040)**	(38,719)
Expenses with utilities and services	**(25,745)**	(18,210)	**(26,560)**	(19,112)
Lease expenses	**(287)**	(655)	**(304)**	(660)
Depreciation and amortization expenses	**(7,720)**	(7,189)	**(7,944)**	(7,376)
Employee profit sharing	**(2,958)**	(151)	**(2,991)**	(155)
Management profit sharing	**(8,965)**	(6,779)	**(8,965)**	(6,779)
Banking expenses	**(357)**	(987)	**(361)**	(996)
Management compensation	**(4,178)**	(3,789)	**(4,178)**	(3,790)
Software maintenance and licensing expenses	**(9,687)**	(7,161)	**(9,789)**	(7,254)
Consumption expenses	**(415)**	(395)	**(450)**	(449)
Insurance expenses	**(181)**	(194)	**(250)**	(253)
Other administrative expenses	**(6,044)**	(5,558)	**(6,149)**	(5,761)
Total	**(102,477)**	(88,878)	**(104,981)**	(91,304)

(In thousands of reais)

28. Other operating income (expenses)

	Quarter			
	Individual		Consolidated	
	06/30/2026	06/30/2025	**06/30/2026**	06/30/2025
Non-recurring income	**3,531**	354	**3,537**	358
Income from property rental	**50**	48	**50**	48
Recovery of credits	**14,098**	-	**14,288**	-
Refund of cash difference	**121**	92	**121**	92
Cost of sales/disposal of property, plant and equipment	**(885)**	(503)	**(895)**	(513)
Other operating income (expenses)	**(10,539)**	(158)	**(10,504)**	(223)
Total	**6,376**	(167)	**6,597**	(238)

	Accumulated			
	Individual		Consolidated	
	06/30/2026	06/30/2025	**06/30/2026**	06/30/2025
Non-recurring income	**4,312**	1,111	**4,321**	1,119
Income from property rental	**98**	93	**98**	93
Recovery of credits	**17,185**	14,741	**17,375**	14,741
Refund of cash difference	**217**	218	**217**	218
Cost of sales/disposal of property, plant and equipment	**(1,093)**	(638)	**(1,140)**	(707)
Other operating income (expenses)	**(10,595)**	(138)	**(10,539)**	(19)
Total	**10,124**	15,387	**10,332**	15,445

29. Finance income and costs

29.1 Breakdown of finance income

	Quarter			
	Individual		Consolidated	
	06/30/2026	06/30/2025	**06/30/2026**	06/30/2025
Finance income				
Interest on assets (*)	**138**	2,563	**137**	2,460
Inflation adjustment and exchange differences	**1,471**	805	**1,471**	818
Income from short-term investments	**7,067**	3,916	**8,374**	4,926
Tax on finance income	**(335)**	(353)	**(345)**	(397)
Fair value adjustment of derivative instruments	**-**	2,452	**-**	2,452
Other finance income	**13**	410	**25**	409
Total	**8,354**	9,793	**9,662**	10,668

(*) This line records interest on assets, and the most significant item is inflation adjustment of tax credits.

(In thousands of reais)

	Accumulated			
	Individual		Consolidated	
	06/30/2026	06/30/2025	**06/30/2026**	06/30/2025
Finance income				
Interest on assets (*)	**1,290**	7,171	**1,290**	6,899
Inflation adjustment and exchange differences (**)	**6,157**	10,236	**6,157**	10,249
Income from short-term investments	**17,055**	6,526	**19,499**	9,595
Financial discounts obtained	**16**	-	**28**	
Tax on finance income	**(852)**	(697)	**(881)**	(780)
Fair value adjustment of derivative instruments	**-**	3,573	**-**	3,573
Other finance income	**-**	621	**-**	622
Total	**23,666**	27,430	**26,093**	30,158

(*) This line records interest on assets, and the most significant item is inflation adjustment of tax credits.
(**) This line records monetary gains and exchange differences, and the most significant item is operation 4131.

29.2 Breakdown of finance costs

	Quarter			
	Individual		Consolidated	
	06/30/2026	06/30/2025	**06/30/2026**	06/30/2025
Finance costs				
Interest on financing	**(17,387)**	(12,357)	**(17,793)**	(12,787)
Interest on intragroup loans	**-**	(629)	**-**	-
Interest expenses	**(909)**	(170)	**(909)**	(252)
Discounts granted/bonuses	**(45)**	(165)	**(126)**	(200)
Inflation adjustment and exchange differences	**(1,448)**	(4,699)	**(1,447)**	(4,699)
Interest on leases	**(20,054)**	(17,325)	**(20,054)**	(17,325)
Fair value adjustment of derivative instruments	**-**	(2,313)	**-**	(2,313)
Other finance costs	**(452)**	(484)	**(453)**	(581)
Total	**(40,295)**	(38,142)	**(40,782)**	(38,157)

	Accumulated			
	Individual		Consolidated	
	06/30/2026	06/30/2025	**06/30/2026**	06/30/2025
Finance costs				
Interest on financing	**(35,886)**	(26,702)	**(36,737)**	(27,533)
Interest on intragroup loans	**(169)**	(629)	**-**	-
Interest expenses	**(2,004)**	(328)	**(2,005)**	(419)
Discounts granted/bonuses	**(173)**	(707)	**(411)**	(802)
Inflation adjustment and exchange differences	**(2,926)**	(6,460)	**(2,926)**	(6,460)
Interest on leases	**(39,940)**	(34,162)	**(39,940)**	(34,162)
Fair value adjustment of derivative instruments	**(5,063)**	(11,159)	**(5,063)**	(11,159)
Other finance costs	**(1,121)**	(978)	**(1,122)**	(1,169)
Total	**(87,282)**	(81,125)	**(88,204)**	(81,704)

(In thousands of reais)

30. Transactions with related parties

30.1 Balances and transactions

The total amounts of transactions carried out with related parties, up to June 30, 2026, are shown in the following table. Such transactions occurred in the normal course of business are carried out under the conditions established in the contract between the parties and observe market conditions.

For the purposes of presenting the consolidated financial statements, the balances and transactions between the companies of the Dimed Group are eliminated in full, as provided for by the accounting practices adopted in Brazil and in accordance with international accounting standards (IFRS).

Assets	**Relationship**	**Nature of transaction**	**06/30/2026**	12/31/2025
Dimesul	Parent	Loan (i)	**-**	27,000
Lifar Industria	Parent	Trade accounts receivable	**12,311**	8,971

Profit or loss	**Relationship**	**Nature of transaction**	**06/30/2026**	06/30/2025
Lifar Industria	Parent	Sale of goods and services	**29,994**	29,410
Dimesul	Parent	Revenue from services rendered	**704**	842
Dimesul	Parent	Finance income	**169**	629
Lifar Industria	Parent	Finance costs	**-**	(289)

(i) Intragroup loans transactions take into account the borrowing rate of current credit lines. In the transaction with the subsidiary Dimesul Gestão Imobiliária Ltda., the amounts are adjusted for inflation considering the rate of 7.42% p.a. The intragroup loan was settled in January 2026.

30.2 Key management personnel compensation

The table below contains information on key management personnel compensation (individual):

	Quarter		**Accumulated**	
	Individual		**Individual**	
	06/30/2026	06/30/2025	**06/30/2026**	06/30/2025
Fixed compensation	**2,114**	1,940	**4,178**	3,790
Social charges	**592**	543	**1,170**	1,061
Equity interest	**7,147**	5,050	**8,965**	6,779
Total	**9,853**	7,533	**14,313**	11,630

These amounts are stated under “General and administrative expenses” in the statement of profit or loss and are detailed in Note 27. Management is also part of the Incentive Plan in connection with the Company’s shares, created to regulate the possibility of granting incentives through common shares issued by the Company.

Managing officers were granted the right to receive, free of charge, the proportion of 3 (three) to 5 (five) Matching Shares for each common share of the Company, acquired under the Plan (“Own shares”), up to the limit established in their respective Private Share Granting Instruments and Adhesion to the Matching Shares Plan, provided that certain conditions are met. The Company recognized at fair value, which corresponds to the Matching Shares of managing officers, an amount of R$2,738 until the second quarter of 2026. Additional information can be found in Note 23.3.

31. Insurance coverage

The Company has insurance policies that consider the nature and degree of risks involved. As at June 30, 2026, the Company and its subsidiaries had insurance coverage for vehicles, flood, fire, civil liability, cargo transportation and aircraft, among others. The insurance coverage sufficiency is under the responsibility of the Company's Executive Board that considers it adequate to cover losses, if any. The Maximum Indemnification Limits for the main insurance policies are as follows:

Polices	Amounts in thousands of R$
Vehicles	FIPE Table + Property Damage + Bodily Injury
Fire	R$ 706,899
Civil liability	R$ 31,200
Aircraft	R$ 23,945*
Civil liability - aircraft	R$ 129,400*

(*) Policy issued in US dollar, translated at the average rate (US dollar) of 06/30/2026 (R$ 5.1760).

(Convenience Translation into English from the Original Previously Issued in Portuguese)

REPORT ON REVIEW OF INDIVIDUAL AND CONSOLIDATED INTERIM FINANCIAL INFORMATION

To the Shareholders and Management of

Dimed S.A. Distribuidora de Medicamentos

Eldorado do Sul - RS

Introduction

We have reviewed the accompanying individual and consolidated interim financial information of Dimed S.A. Distribuidora de Medicamentos ("Company"), included in the Quarterly Information Form (ITR) for the quarter ended June 30, 2026, which comprises the balance sheet as at June 30, 2026 and the related statements of profit or loss and of comprehensive income for the three- and six-month periods then ended, and of changes in equity and of cash flows for the six-month period then ended, including the material accounting policies and explanatory notes.

Management is responsible for the preparation of the individual and consolidated interim financial information in accordance with technical pronouncement CPC 21 (R1) and international standard IAS 34 - Interim Financial Reporting, as well as for the presentation of such information in accordance with the standards issued by the Brazilian Securities and Exchange Commission (CVM). Our responsibility is to express a conclusion on this individual and consolidated interim financial information based on our review.

Scope of review

We conducted our review in accordance with Brazilian and international standards on review of interim financial information (NBC TR 2410 and ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the standards on auditing and, consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion on the individual and consolidated interim financial information

Based on our review, nothing has come to our attention that causes us to believe that the accompanying individual and consolidated interim financial information is not prepared, in all material respects, in accordance with technical pronouncement CPC 21 (R1) and international standard IAS 34, and presented in accordance with the standards issued by the CVM.

Other matters

Statements of value added

The individual and consolidated interim financial information referred to above includes the individual and consolidated Statements of Value Added (DVA) for the six-month period ended June 30, 2026, prepared under the responsibility of the Company's Management and disclosed as supplemental information for purposes of the international standard IAS 34. These statements were subject to review procedures performed together with the review of the interim financial information to reach a conclusion on whether they are reconciled with the interim financial information and the accounting records, as applicable, and whether their form and content are in accordance with the criteria set out in technical pronouncement CPC 09 (R1) - Statement of Value Added. Based on our review, nothing has come to our attention that causes us to believe that such statements of value added are not prepared, in all material respects, in accordance with the criteria set out in such technical pronouncement and consistently with the individual and consolidated interim financial information taken as a whole.

The accompanying individual and consolidated interim financial information has been translated into English for the convenience of readers outside Brazil.

Porto Alegre, August 6, 2026

DELOITTE TOUCHE TOHMATSU
Auditores Independentes Ltda.

Jonas Dal Ponte
Engagement Partner

Dimed S.A. Distribuidora de Medicamentos

grupo panvel

Reports and Representations / Report or Summary Report, if any, of the Audit Committee (statutory or not)

Pursuant to the Articles of Incorporation and legal provisions, the Audit Committee of Dimed S.A. Distribuidora de Medicamentos examined the Management Report and the Financial Statements for the quarter ended June 30, 2026. Based on the examinations carried out, considering, furthermore, the unqualified independent auditor’s report issued by Deloitte Touche Tohmatsu Auditores Independentes Ltda., dated August 06, 2026, as well as the information and clarifications received over the quarter, the Audit Committee is unanimously of the opinion that the referred to information is fairly presented.

Eldorado do Sul, RS, August 06, 2026.

João Verner Juenemann
Claudio Roberto Ely
Gilberto Carlos Monticelli

Dimed S.A. Distribuidora de Medicamentos

grupo panvel

Reports and Representations / Officers' Representation on Financial Statements

In accordance with item II of paragraph 1, article 31 of CVM Ruling No, 80 of March 29, 2022, the Executive Board members of Dimed S.A, Distribuidora de Medicamentos, undersigned, represent that they have reviewed, discussed and agreed with the information contained in the Company's Quarterly Information for the quarter ended June 30, 2026.

Eldorado do Sul, RS, August 06, 2026.

Julio Ricardo Mottin Neto – Chief Executive Officer (CEO)
Roberto Coimbra Santos – Executive Officer
Antônio Carlos Tocchetto Napp – Financial and Investor Relations Officer

Dimed S.A. Distribuidora de Medicamentos

Reports and Representations Officers' Representation on the Independent Auditor's Report

In compliance with the provisions contained in article 31 of CVM Ruling No, 80 of March 29, 2022, the Officers of Dimed S.A. Distribuidora de Medicamentos represent that they have reviewed, discussed and agreed with the opinion expressed in the audit report issued by Deloitte Touche Tohmatsu Auditores Independentes Ltda. on the individual and consolidated financial statements for the quarter ended June 30, 2026.

Eldorado do Sul, RS, August 06, 2026.

Julio Ricardo Mottin Neto – Chief Executive Officer (CEO)
Roberto Coimbra Santos – Executive Officer
Antônio Carlos Tocchetto Napp – Financial and Investor Relations Officer